<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Colorectal Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Colorectal Dis</journal-id><journal-title-group><journal-title>International Journal of Colorectal Disease</journal-title></journal-title-group><issn pub-type="ppub">0179-1958</issn><issn pub-type="epub">1432-1262</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40402271</article-id><article-id pub-id-type="pmc">PMC12098509</article-id>
<article-id pub-id-type="publisher-id">4904</article-id><article-id pub-id-type="doi">10.1007/s00384-025-04904-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Diagnostic value of genetic and epigenetic biomarker panels for colorectal cancer detection: a systematic review</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Alampritis</surname><given-names>Georgios</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Thoukididou</surname><given-names>Sarah Nohelia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ramos</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Georgiou</surname><given-names>Pantelis</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kalofonou</surname><given-names>Melpomeni</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Simillis</surname><given-names>Constantinos</given-names></name><address><email>csimillis@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013meh722</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2188 5934</institution-id><institution>Department of Surgery, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041kmwe10</institution-id><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution>Department of Electrical and Electronic Engineering, </institution><institution>Imperial College London, </institution></institution-wrap>London, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04v54gj93</institution-id><institution-id institution-id-type="GRID">grid.24029.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0383 8386</institution-id><institution>Cambridge Colorectal Unit, Addenbrookes Hospital, </institution><institution>Cambridge University Hospitals NHS Foundation Trust, </institution></institution-wrap>Cambridge, UK </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>40</volume><issue>1</issue><elocation-id>125</elocation-id><history><date date-type="accepted"><day>29</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Exploration of effective screening methods is imperative to improve current screening for colorectal cancer (CRC). Our aim was to systematically search the literature to identify and assess the diagnostic accuracy of both genetic and epigenetic biomarker panels for CRC detection using liquid biopsies for circulating tumour DNA (ctDNA) from stool, blood, or urine.</p></sec><sec><title>Methods</title><p id="Par2">A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) with searches in Medline, Embase, CENTRAL, and Web Of Science from inception up to March 20, 2025, using pre-defined keywords. Study quality assessment was performed using QUADAS-2 tool (Quality Assessment for Diagnostic Accuracy Studies 2). Primary and secondary outcomes were panel performance (sensitivity and specificity) for CRC, advanced precancerous lesions (APL), and staging of disease.</p></sec><sec><title>Results</title><p id="Par3">Forty-four studies were included. Exceptional performance for both CRC (sensitivity and specificity) and APL (sensitivity) was displayed by biomarker panels including methylated SDC2 with methylated SFRP1/2 (CRC: 91.5%/97.3%, APL: 89.2%) or methylated TFPI2 (CRC: 94.9%/98.1%, APL: 100%), and a 5-biomarker panel of mutational targets APC, Bat-26, KRAS, L-DNA, and p53 (CRC: 91.0%/93.0%, APL: 82.0%). Suboptimal APL sensitivities up to 57.0% were exhibited by Cologuard and variant panels (including KRAS, methylated BMP3, methylated NDRG4, FIT), and 47.8% for combinations including methylated SEPT9.</p></sec><sec><title>Conclusions</title><p id="Par4">High-performance, candidate ctDNA biomarker panels with exceptional diagnostic accuracy for both CRC and APL have been identified. Further work should focus on the development of large-scale studies to justify their clinical implementation.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colorectal cancer</kwd><kwd>Detection</kwd><kwd>Biomarker panels</kwd><kwd>Genetic</kwd><kwd>Epigenetic</kwd><kwd>CtDNA</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><sec id="Sec2"><title>Colorectal cancer background</title><p id="Par5">Improved understanding of the pathophysiology of colorectal cancer (CRC) is a promising avenue for efficient and fast-tracked screening. CRC ranks third in cancer incidence worldwide and is the second highest cancer-related cause of death, estimated at 935,000 deaths in 2020 [<xref ref-type="bibr" rid="CR1">1</xref>]. These rates vary geographically with the highest seen in the most developed countries.</p><p id="Par6">With the evolving field of evidence, CRC has been suggested to be a marker of socioeconomic development due to the trend of uniform rise in incidence rates with increasing Human Development Index (HDI) in countries undergoing major economic transition [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Development of CRC is attributable to both hereditary and environmental risk factors. The upward incidence in transitioning countries reflects changes in modifiable environmental factors such as lifestyle and diet including increased level of cigarette smoking, intake of processed animal products including red meat, decreased physical activity, excess body fat, and heavy alcohol consumption [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par7">A proportion of high-incidence countries have experienced a decline in colorectal cancer rates due to public health campaigns incorporating screening programmes and population-based education regarding healthier lifestyles. Increased colonoscopy screenings alongside stool-based haemoglobin detection, has supported the detection and removal of precursor lesions [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Despite the promising trends for adults over 50 years old, it has been noticed that a higher proportion of adults under 50 years present with early-onset colorectal cancers with the incidence rising by 1&#x02013;4% per year depending on the region [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The rising incidence and burden of early-onset cancers (age &#x0003c;&#x02009;50 years) has forced the American Cancer Society to lower the recommended screening age for average risk individuals from 50 to 45 years in 2018 [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par8">CRC cancer prognosis and long-term survival is highly influenced by the TNM staging at time of diagnosis. Right-sided CRCs typically present with anaemia, fatigue, weight loss, and abdominal pain, or cramping, whilst left-sided CRCs with rectal bleeding and change in bowel habit [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. A substantial proportion of patients are asymptomatic and only 14% of CRCs are diagnosed at an early stage, highlighting the importance of effective screening and improving early diagnosis [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par9">CRC is a heterogenous disease with several carcinogenic pathways exhibiting a variety of genetic and epigenetic alterations [<xref ref-type="bibr" rid="CR13">13</xref>]. Three major precursor lesion pathways are recognised: Chromosomal Instability (CIN), Microsatellite Instability (MSI), and the Serrated Pathway/CpG Island Methylator Pathway (CIMP). The CIN pathway represents the traditional adenoma-carcinoma sequence model, primarily associated with left-sided CRCs, featuring activating mutations in proto-oncogenes such as KRAS (Kirsten rat sarcoma viral oncogene homolog) and inactivating mutations in tumour suppressor genes such as APC (adenomatous polyposis coli) and subsequently TP53 (tumour protein p53) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] In contrast, the MSI pathway is more prevalent in right-sided CRCs and is marked by defective DNA mismatch repair (MMR), leading to hypermutated tumours and genomic instability due to the accumulation of single nucleotide mutations [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Lastly, the Serrated Pathway is characterised by hypermethylation of genes and BRAF (B-Raf proto-oncogene) mutations, resulting in enhanced MAPK/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase) signalling and uncontrolled proliferation, with further hypermethylation of the tumour suppressor gene p16 promoting carcinogenesis [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Nevertheless, each tumour has its unique genomic profile, implying that there is interaction between the aforementioned pathways in the carcinogenesis route.</p></sec><sec id="Sec3"><title>Critical literature review</title><p id="Par10">The current CRC screening methods include colon structure-based, image-based, and biological sample-based tests. The gold standard and current standard of care of CRC screening is colonoscopy, with high sensitivity and specificity, and potential for direct removal of early cancers and precancerous lesions at the time of detection. The disadvantages of colonoscopy include invasiveness, high costs, risk of bowel perforation, need for bowel preparation, and possible sedation which have direct impact on the uptake of the test and participation in screening programmes [<xref ref-type="bibr" rid="CR20">20</xref>]. The effectiveness of a screening program depends not only on the screening test performance, but also on patient adherence to achieve a high participation rate, which is affected by the burden of the test, risk of complications, the cost, cultural beliefs of the individual and logistics of carrying out the test [<xref ref-type="bibr" rid="CR6">6</xref>]. CT Colonography can be a useful semi-invasive alternative in selected cases; however, it has its own disadvantages, including ionising radiation, full bowel preparation, high costs, dependence on radiologist&#x02019;s technical expertise for accurate interpretation, and the requirement for follow-up colonoscopy in the event of abnormalities. Consequently, it is not considered appropriate for population screening [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par11">Non-invasive stool tests detecting faecal haemoglobin, the guaiac faecal occult blood test (gFOBT) and the faecal immunochemical test (FIT), are alternatives currently being used in two-step screening programmes. The FIT is the preferred method of screening over gFOBT due to its superior test characteristics (higher sensitivity, one stool sample needed for multiple FIT tests), lack of need for medication or dietary changes, and greater adherence rates [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Additionally, a meta-analysis reported a pooled FIT sensitivity of 79% and specificity of 94%, with however large heterogeneity in included studies due to the use of different cut-offs for a positive result [<xref ref-type="bibr" rid="CR23">23</xref>]. Despite a demonstrated overall reduction in CRC mortality by FOBT-based organised screening programmes, the FOBTs (FIT and gFOBT) display a relatively low performance for detecting precancerous lesions and thus are mainly used for detecting advanced colorectal neoplasms [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par12">Recent advancements in CRC detection strategies utilise liquid biopsies for high yield, non-invasive tests. Liquid biopsies consist of a sample of any bodily fluid that contain genetic material from a tumour such as blood, faeces, or urine. Compared to single tissue biopsy, they provide a better characterisation of cancer genome [<xref ref-type="bibr" rid="CR25">25</xref>]. They use circulating materials such as circulating tumour DNA (ctDNA; cell-free DNA of tumour origin), circulating tumour cells (CTCs), cell-free miRNA, and cell-derived vesicles (such as exosomes) to detect molecular alterations present in carcinogenesis [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. ctDNA compared to CTCs in cancer patients, was observed to be more specific for DNA mutations and in higher numbers [<xref ref-type="bibr" rid="CR28">28</xref>]. Specifically, ctDNA is derived from apoptotic and necrotic tumour cells releasing fragmented DNA into the circulation or stool, reflecting the genetic and epigenetic alterations of the original tumour cells and their corresponding microenvironment [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Interestingly, in some instances, the early stages of carcinogenesis are marked by many epigenetic changes before any somatic mutations and histopathological changes can be detected [<xref ref-type="bibr" rid="CR30">30</xref>]. Hence, the combinatory mutational and epigenetic analysis of liquid biopsies is representing a promising tool with mass screening potential.</p><p id="Par13">Cologuard&#x000ae; is the first FDA-approved multitarget stool DNA test in 2014 (mt-sDNA) that combines both DNA and FIT testing for detection of abnormal DNA and faecal haemoglobin in stool samples. The DNA molecular assays test for methylated BMP3 and NDRG4, mutant KRAS and &#x003b2;-actin (reference gene). In a large multi-centre, cross-sectional study reported by Imperiale et al. [<xref ref-type="bibr" rid="CR31">31</xref>]<italic>,</italic> the higher sensitivity for CRC (92.3% vs 73.8%) and advanced adenomas (42.4% vs 23.8%) is accompanied by a lower specificity (86.6% vs 94.9%), compared to FIT testing alone. Apart from the higher costs when using multi-target panels, a higher number of patients were excluded due to problematic faecal DNA testing (<italic>n</italic>&#x02009;= 689; sample integrity, technical failure, missing samples) compared to FIT testing alone (<italic>n</italic>&#x02009;= 34; insufficient haemoglobin sample) which highlights the complexity of stool sample collection and analysis. This further highlights the necessity of investigating sources beyond stool for ctDNA panels.</p></sec><sec id="Sec4"><title>Rational, aim, and objectives</title><p id="Par14">The use of individual biomarkers has been shown to yield an inferior performance compared to the combination of several biomarkers in a panel. Since the approval of Cologuard&#x000ae;, several other candidate biomarkers panels (including variations of mt-sDNA) using liquid biopsies have been extensively investigated in an attempt to identify a superior panel comprised of both genetic and epigenetic biomarkers. Special consideration for those panels should be a higher performance for the detection of advanced precancerous lesions, including advanced adenomas, as this can benefit early detection and cure. To the best of our knowledge, the current literature lacks a systematic reporting of liquid biopsy biomarker panels that extend beyond a single ctDNA source (whether from faecal or blood material) or a specific focus on DNA methylation. Thus, our aim was to systematically search the literature to identify and assess the diagnostic accuracy, in terms of sensitivity and specificity, of genetic and epigenetic ctDNA biomarkers panels for CRC detection using specimens of stool, blood, or urine. Additionally, to further determine the extent of detecting advanced precancerous lesions and differentiating between different stages of CRC disease (I&#x02013;IV).</p></sec></sec><sec id="Sec5"><title>Methodology</title><sec id="Sec6"><title>Search strategy</title><p id="Par15">A systematic literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and was registered in PROSPERO (CRD420251017969), where the review protocol can be accessed [<xref ref-type="bibr" rid="CR32">32</xref>]. Systematic searches were performed in four main bibliographic databases: Medline, Embase, CENTRAL, and Web Of Science from inception up to March 20, 2025. The search query included the following keywords starting with five isolated searches and lastly combining the searches for each database: &#x0201c;(colorectal cancer OR colon cancer OR rectal cancer) AND (biomarker OR genetic OR epigenetic OR methylated DNA OR hypermethylated DNA) AND (circulating tumour DNA OR plasma cell-free DNA OR liquid biopsy OR stool DNA) AND (screening OR diagnosis OR detection OR prediction OR prognosis OR treatment OR management) AND (panel* OR multi-gene OR multigene OR multi-target OR multitarget OR multi-test OR multitest)&#x0201d;. All articles published in the English language in peer-review academic journals were selected for further review. Additionally, references of systematic reviews and meta-analyses were searched manually for identification of any other eligible studies.</p></sec><sec id="Sec7"><title>Eligibility assessment</title><p id="Par16">Screening of articles was performed by two independent reviewers (GA, ST) through titles, abstracts, and full-texts against the pre-defined eligibility criteria. Any conflicts were resolved by a third reviewer. Studies were included if they reported on the performance (sensitivity and specificity) of a ctDNA biomarker panel (defined as having at least 2 biomarkers &#x02013; genetic and/or epigenetic) for detecting CRC (and also advanced precancerous lesions if applicable).</p><p id="Par17">Our exclusion criteria were as follows: (1) studies on any type of cancer other than colorectal, (2) literature reviews, systematic reviews, meta-analyses, conference abstracts, editorials, doctoral theses, letters to the editor and comments, (3) studies not focusing on genetic (mutation) and epigenetic (methylation) biomarker panels for screening, detection, or diagnosis of colorectal cancer; also, those reporting only for individual biomarkers, (4) wrong outcome such as treatment response/monitoring, prognosis, cost-effectiveness, post-treatment recurrence, pre/post-treatment phase, (5) any sources of DNA other than blood, stool, or urine; also, no source of DNA reported, using non-ctDNA from blood samples (e.g., cf-nucleosomes, miRNAs) and proteomics, (6) studies without human samples including in silico studies, animal models, or cell-lines, (7) data only for advanced precancerous lesions, (8) studies with inflammatory bowel disease or hereditary CRC syndrome patients, and (9) studies that did not report sample sizes.</p></sec><sec id="Sec8"><title>Data extraction and analysis</title><p id="Par18">Primary outcomes of interest were composite sensitivity and specificity of biomarker panels for CRC detection with sensitivity defined as the percentage of CRC patients with detected ctDNA aberrations and specificity defined as the percentage of healthy individuals without detected ctDNA aberrations. Secondary outcomes included performance to detect advanced precancerous lesions (APLs) defined as advanced adenomas of &#x02265;&#x02009;1 cm diameter or villous architecture on histology or high-grade dysplasia, and serrated polyps &#x02265;&#x02009;1 cm, and CRC at different stages of disease determined by the AJCC (American Joint Committee on Cancer) staging system [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Additionally, data were extracted for patient characteristics (sample size, age, sex), ctDNA source, method of analysis, biomarkers included and study type (case&#x02013;control or cohort type of cross-sectional study) using a validated algorithm [<xref ref-type="bibr" rid="CR35">35</xref>], for diagnostic accuracy studies. Data were tabulated in Excel Version 16.85.</p></sec><sec id="Sec9"><title>Quality assessment</title><p id="Par19">Quality assessment of all included studies was performed using the validated Quality Assessment for Diagnostic Accuracy Studies 2 tool (QUADAS-2) to evaluate risk of bias and applicability concerns for four key domains: patient selection, index tests, reference standards, and flow and timing. Signalling questions were used to assist in rating the domains as &#x0201c;low&#x0201d;, &#x0201c;high&#x0201d;, or &#x0201c;unclear&#x0201d; in terms of risk of bias and applicability. Review Manager 5 software Version 5.4 was used for managing the QUADAS-2 data and creating figures [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>PRISMA flow diagram</title><p id="Par20">The systematic search yielded a total of 1007 eligible abstracts, with 996 from four databases and 11 identified through citation searching. After duplicate removal (<italic>n</italic>&#x02009;= 305), 702 articles were screened by title and abstract for eligibility, excluding 614 for various reasons leaving 88 articles for full-text retrieval (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). From those, 44 further articles were eliminated resulting to 44 articles to be included in the review, based on our inclusion and exclusion criteria.<fig id="Fig1"><label>Fig. 1</label><caption><p>The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the inclusion of the studies</p></caption><graphic xlink:href="384_2025_4904_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec12"><title>Quality assessment of included studies</title><p id="Par21">Only 2 studies scored low risk in all domains of the quality assessment on the QUADAS-2 tool (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]<italic>.</italic> The majority of studies (<italic>n</italic>&#x02009;= 42) scored unclear or high risk of bias on at least one domain, predominantly patient selection with 66% (<italic>n</italic>&#x02009;= 29) unclear and 27% (<italic>n</italic>&#x02009;= 12) high risk of bias (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). This was due to several case&#x02013;control study designs and lack of detailed information on the nature of patient selection process, especially on the sampling method employed, which may introduce sampling bias. In the other 3 domains of risk of bias (index test, reference standard, and flow and timing), more than half of the papers scored low risk of bias. An unclear rating was due to incomplete information on the use of a pre-specified panel cut-off value, colonoscopy process and timing, or blinding during interpretation of index and reference standard. In terms of applicability concerns, many papers (59%, <italic>n</italic>&#x02009;= 26) scored low risk in all domains, with several papers lacking again (high or unclear risk) on the patient selection domain (39%, <italic>n</italic>&#x02009;= 17) due to the patient selection process and study design.<fig id="Fig2"><label>Fig. 2</label><caption><p>Risk of bias and applicability concerns summary: review authors&#x02019; judgements about each domain for each included study</p></caption><graphic xlink:href="384_2025_4904_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Risk of bias and applicability concerns graph: review authors&#x02019; judgements about each domain presented as percentages and counts across included studies</p></caption><graphic xlink:href="384_2025_4904_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec13"><title>Study characteristics</title><p id="Par22">The systematic review includes 44 studies with a total sample size of 30803 consisting of 48% (14047) male and 52% (14936) female participants (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The weighted mean (&#x000b1; SD) age of participants amongst all the studies was 61 &#x000b1;&#x02009;5 years. The mean age amongst specific groups, was 64 &#x000b1;&#x02009;4 years for the CRC group, 63 &#x000b1;&#x02009;4 years for the APL group, and 58 &#x000b1;&#x02009;9 years for the control group.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Study</th><th align="left" rowspan="2">Cross-sectional study subdesign</th><th align="left" rowspan="2" colspan="2">Biomarkers</th><th align="left" rowspan="2">ctDNA source</th><th align="left" rowspan="2">n</th><th align="left" rowspan="2">Sex (M/F)</th><th align="left" colspan="4">Age</th></tr><tr><th align="left">&#x003bc;</th><th align="left">CRC</th><th align="left">APL</th><th align="left">C</th></tr></thead><tbody><tr><td align="left">Ahlquist 2000 [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">APC, Bat-26, KRAS, L-DNA, p53</td><td align="left">Stool</td><td align="left">61</td><td align="left">30/31</td><td align="left">70</td><td align="left">70</td><td align="left">73</td><td align="left">68</td></tr><tr><td align="left">Ahlquist 2012 [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">KRAS, mBMP3, mNDRG4, mTFPI2, mVIM, &#x003b2;-actin, Haemoglobin</td><td align="left">Stool</td><td align="left">678</td><td align="left">339/339</td><td align="left">60</td><td align="left">-</td><td align="left">-</td><td align="left">57</td></tr><tr><td align="left">Bach 2021 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mSDC2, mSEPT9</td><td align="left">Urine</td><td align="left">155</td><td align="left">76/79</td><td align="left">65</td><td align="left">66</td><td align="left">-</td><td align="left">62</td></tr><tr><td align="left">Bartak 2017 [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mPRIMA1, mSDC2, mSFRP1, mSFRP2</td><td align="left">Plasma</td><td align="left">121</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Bosch 2019 [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left">Cohort type</td><td align="left" colspan="2">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (MT-sDNA)</td><td align="left">Stool</td><td align="left">1014</td><td align="left">520/494</td><td align="left">60</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Brenne 2023 [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mBMP3, mFLI1, mIKZF1, mNPTX2, mSFRP1, mSFRP2, mSLC8 A1, mVIM</td><td align="left">Plasma</td><td align="left">143</td><td align="left">66/77</td><td align="left">70</td><td align="left">70</td><td align="left">-</td><td align="left">70</td></tr><tr><td align="left">Cassinotti 2012 [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mCYCD2, mHIC1, mPAX5, mRASSF1 A, mRB1, mSRBC</td><td align="left">Plasma</td><td align="left">90</td><td align="left">-</td><td align="left">64</td><td align="left">68</td><td align="left">62</td><td align="left">61</td></tr><tr><td align="left">Chen Y 2019 [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mSDC2, mSEPT9 (ColoDefense)</td><td align="left">Serum</td><td align="left">225</td><td align="left">-</td><td align="left">47</td><td align="left">61</td><td align="left">-</td><td align="left">33</td></tr><tr><td align="left">Cheng 2021 [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mADHFE1, mPPP2R5 C, mSDC2</td><td align="left">Stool</td><td align="left">30</td><td align="left">21/9</td><td align="left">55</td><td align="left">63</td><td align="left">63</td><td align="left">41</td></tr><tr><td align="left">Cho 2021 [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mFAM123 A, mGLI3, mPPP1R16B, mSLIT3, mTMEM90B</td><td align="left">Plasma</td><td align="left">157</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Ciarloni 2016 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">29 gene panel, CEA, CYFRA21-1</td><td align="left">Plasma</td><td align="left">349</td><td align="left">194/155</td><td align="left">65</td><td align="left">69</td><td align="left">67</td><td align="left">61</td></tr><tr><td align="left">Fan 2023 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (ColoClear MT-sDNA), CEA, 6 genera of gut microbiota</td><td align="left">Stool</td><td align="left">105</td><td align="left">61/44</td><td align="left">60</td><td align="left">65</td><td align="left">-</td><td align="left">54</td></tr><tr><td align="left">Gagrat 2024 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mLASS4, mLRRC4, mPPP2R5 C, mZDHHC1, Haemoglobin</td><td align="left">Stool</td><td align="left">777</td><td align="left">387/390</td><td align="left">64</td><td align="left">-</td><td align="left">-</td><td align="left">63</td></tr><tr><td align="left">He 2010 [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mALX4, mSEPT9, mTMEFF2</td><td align="left">Plasma</td><td align="left">352</td><td align="left">237/115</td><td align="left">59</td><td align="left">58</td><td align="left">-</td><td align="left">60</td></tr><tr><td align="left">Imperiale 2014 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">Cohort type</td><td align="left" colspan="2">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (Cologuard MT-sDNA)</td><td align="left">Stool</td><td align="left">9989</td><td align="left">4625/5364</td><td align="left">64</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Imperiale 2024 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">Cohort type</td><td align="left" colspan="2">mLASS4, mLRRC4, mPPP2R5 C, mZDHHC1, Haemoglobin</td><td align="left">Stool</td><td align="left">7662</td><td align="left">3402/4260</td><td align="left">64</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Itzkowitz 2007 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mVIM, DIA (DNA Integrity Assay)</td><td align="left">Stool</td><td align="left">162</td><td align="left">86/76</td><td align="left">60</td><td align="left">66</td><td align="left">-</td><td align="left">59</td></tr><tr><td align="left">Jiang 2022 [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mPAX8, mRASSF1, mSFRP2, Haemoglobin/FIT</td><td align="left">Stool</td><td align="left">250</td><td align="left">129/121</td><td align="left">69</td><td align="left">69</td><td align="left">-</td><td align="left">68</td></tr><tr><td align="left">Kranenbarg 2021 [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mAKR1B1, mCOL6 A2, mMAL, mTMEFF2, mZNF671</td><td align="left">Plasma</td><td align="left">40</td><td align="left">24/16</td><td align="left">63</td><td align="left">56</td><td align="left">-</td><td align="left">70</td></tr><tr><td align="left">Lee 2009 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mAPC, mMGMT, mRASSF2 A, mWIF1</td><td align="left">Plasma</td><td align="left">583</td><td align="left">-</td><td align="left">-</td><td align="left">61</td><td align="left">-</td><td align="left">58</td></tr><tr><td align="left">Li 2019 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">80 marker panel (including mSEPT9, mIKZF1)</td><td align="left">Plasma</td><td align="left">283</td><td align="left">150/133</td><td align="left">62</td><td align="left">65</td><td align="left">-</td><td align="left">60</td></tr><tr><td align="left">Lidgard 2013 [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (MT-sDNA)</td><td align="left">Stool</td><td align="left">1003</td><td align="left">454/549</td><td align="left">65</td><td align="left">-</td><td align="left">-</td><td align="left">65</td></tr><tr><td align="left">Lin 2022 [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">APC, BRAF, KRAS, mSDC2, mSFRP2</td><td align="left">Stool</td><td align="left">292</td><td align="left">164/128</td><td align="left">58</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Liu 2024 [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mSDC2, mSEPT9, mVIM</td><td align="left">Stool</td><td align="left">33</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Lohsiriwat 2024 [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left">Cohort type</td><td align="left" colspan="2">mADHFE1, mSDC2, mPPP2R5 C</td><td align="left">Stool</td><td align="left">274</td><td align="left">108/166</td><td align="left">62</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Lu 2014 [<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mGATA4/5, mNDRG4, mSFRP2, mVIM</td><td align="left">Stool</td><td align="left">96</td><td align="left">45/51</td><td align="left">60</td><td align="left">60</td><td align="left">-</td><td align="left">60</td></tr><tr><td align="left">Ma 2022 [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mNDRG4, mSDC2, mTFPI2, mWIF1 (ColoCaller)</td><td align="left">Stool</td><td align="left">158</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Melotte 2015 [<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left">Unclear</td><td align="left" colspan="2">mFOXE1, mSYNE1</td><td align="left">Plasma</td><td align="left">306</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Mo 2021 [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">BRAF, KRAS, PI3 KCA, mBMP3, mNDRG4, mSEPT9, FIT, Fusobacterium nucleatum, Parvimonas micra</td><td align="left">Stool</td><td align="left">162</td><td align="left">94/68</td><td align="left">58</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Mu 2020 [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (ColoClear MT-sDNA)</td><td align="left">Stool</td><td align="left">839</td><td align="left">445/394</td><td align="left">59</td><td align="left">62</td><td align="left">60</td><td align="left">57</td></tr><tr><td align="left">Park 2017 [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mBMP3, mNDRG4, mSFRP2, mTFPI2</td><td align="left">Stool</td><td align="left">111</td><td align="left">71/38</td><td align="left">60</td><td align="left">61</td><td align="left">63</td><td align="left">56</td></tr><tr><td align="left">Pasha 2019 [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mRUNX3, mSFRP1, CEA</td><td align="left">Stool</td><td align="left">165</td><td align="left">106/59</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Rasmussen 2017 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mALX4, mBMP3, mNPTX2, mRARB, mSDC2, mSEPT9, mVIM, female, age &#x0003e;&#x02009;66</td><td align="left">Plasma</td><td align="left">295</td><td align="left">174/121</td><td align="left">67</td><td align="left">68</td><td align="left">-</td><td align="left">65</td></tr><tr><td align="left">Sun 2019 [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">KRAS, mSDC2, mSFRP2, Haemoglobin</td><td align="left">Stool</td><td align="left">233</td><td align="left">124/109</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Tagore 2003 [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left">Cohort type</td><td align="left" colspan="2">APC, BAT-26, KRAS, p53, DIA (DNA Integrity Assay)</td><td align="left">Stool</td><td align="left">292</td><td align="left">138/154</td><td align="left">63</td><td align="left">64</td><td align="left">61</td><td align="left">62</td></tr><tr><td align="left">Wang 2021 [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left">Unclear</td><td align="left" colspan="2">mBMP3, mNDRG4, mSDC2, Haemoglobin (sDNA-FOBT)</td><td align="left">Stool</td><td align="left">144</td><td align="left">83/61</td><td align="left">58</td><td align="left">63</td><td align="left">-</td><td align="left">55</td></tr><tr><td align="left">Xu 2021 [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td align="left">Cohort type</td><td align="left" colspan="2">mBCAT1, mSDC2, mSEPT9, CEA, Haemoglobin/FIT</td><td align="left">Plasma, Stool</td><td align="left">294</td><td align="left">192/102</td><td align="left">61</td><td align="left">65</td><td align="left">-</td><td align="left">60</td></tr><tr><td align="left">Yang 2020 [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">KRAS, mNDRG4, mSDC2, mTFPI2, &#x003b2;-actin</td><td align="left">Stool</td><td align="left">151</td><td align="left">71/80</td><td align="left">61</td><td align="left">60</td><td align="left">59</td><td align="left">65</td></tr><tr><td align="left">Young 2021 [<xref ref-type="bibr" rid="CR74">74</xref>]</td><td align="left">Unclear</td><td align="left" colspan="2">mBCAT1, mIKZF1, mIRF4</td><td align="left">Plasma</td><td align="left">1620</td><td align="left">902/718</td><td align="left">63</td><td align="left">67</td><td align="left">-</td><td align="left">60</td></tr><tr><td align="left">Yuan 2016 [<xref ref-type="bibr" rid="CR75">75</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mOSMR, mSEPT9</td><td align="left">Plasma</td><td align="left">321</td><td align="left">163/158</td><td align="left">62</td><td align="left">64</td><td align="left">-</td><td align="left">61</td></tr><tr><td align="left">Zhang 2014 [<xref ref-type="bibr" rid="CR76">76</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mSFRP2, mWIF1</td><td align="left">Stool</td><td align="left">145</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Zhang 2021 [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mSDC2, mTFPI2</td><td align="left">Stool</td><td align="left">130</td><td align="left">76/54</td><td align="left">55</td><td align="left">59</td><td align="left">-</td><td align="left">49</td></tr><tr><td align="left">Zhao 2019 [<xref ref-type="bibr" rid="CR78">78</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mSDC2, mSEPT9 (ColoDefense)</td><td align="left">Plasma</td><td align="left">384</td><td align="left">214/170</td><td align="left">50</td><td align="left">62</td><td align="left">59</td><td align="left">37</td></tr><tr><td align="left">Zhao 2021 [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left">Case&#x02013;control type</td><td align="left" colspan="2">mSDC2, mSFRP2 (SpecColon)</td><td align="left">Stool</td><td align="left">129</td><td align="left">76/53</td><td align="left">60</td><td align="left">61</td><td align="left">67</td><td align="left">44</td></tr><tr><td align="left" colspan="2"/><td align="left"/><td align="left" colspan="4"><bold><italic>Total/Mean (if applicable): 30,803 14,047/14936</italic></bold></td><td align="left"><bold><italic>61</italic></bold></td><td align="left"><bold><italic>64</italic></bold></td><td align="left"><bold><italic>63</italic></bold></td><td align="left"><bold><italic>58</italic></bold></td></tr><tr><td align="left" colspan="2"/><td align="left"/><td align="left" colspan="4"><bold><italic>Standard Deviation:</italic></bold></td><td align="left"><bold><italic>5</italic></bold></td><td align="left"><bold><italic>4</italic></bold></td><td align="left"><bold><italic>4</italic></bold></td><td align="left"><bold><italic>9</italic></bold></td></tr></tbody></table><table-wrap-foot><p><italic>n</italic>, sample size; <italic>M/F</italic>, males/females; <italic>&#x003bc;</italic>, weighted mean of participants; <italic>CRC</italic>, colorectal cancer; <italic>APL</italic>, advanced adenomas of &#x02265;&#x02009;1 cm diameter or villous architecture on histology or high-grade dysplasia; and serrated polyps &#x02265;&#x02009;1 cm; <italic>C</italic>, controls; <italic>&#x02018;&#x02019;- &#x02018;&#x02019;</italic>, not specified/cannot be inferred from data. The pooled comparisons were performed using the available data from full texts or supplementary materials, but despite this there were instances data were not reported or have not been specific enough to be included in the inter-group comparisons</p></table-wrap-foot></table-wrap></p><p id="Par23">There were 35 (80%) case&#x02013;control type cross-sectional studies, 6 (14%) cohort-type cross-sectional studies and 3 (6%) studies with an unclear design. Few studies stated the exact study design in their full-text; for these we had to derive the cross-sectional sub design using the available information in the methodology section. In some cases, methodological information including chronological details was limited.</p><p id="Par24">With regards to the circulating tumour DNA source (ctDNA), there were 27 (62%) studies using stool samples only, 15 (34%) studies using blood samples only (14 plasma and 1 serum), 1 (2%) study with urine sample, and 1 (2%) study with both plasma and stool samples. There were several methods used to analyse ctDNA, the majority of which were PCR-based (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The most commonly used were MSP (Methylation Specific Polymerase Chain Reaction) in 22% (<italic>n</italic>&#x02009;= 10) and quantitative MSP in 20% (<italic>n</italic>&#x02009;= 9), followed by PCR and quantitative PCR in 11% (<italic>n</italic>&#x02009;= 5), respectively for each. The remaining eight methods occupy 36% (<italic>n</italic>&#x02009;= 17).<fig id="Fig4"><label>Fig. 4</label><caption><p>Count and percentage of different ctDNA analysis methods amongst studies. ctDNA =&#x02009;circulating tumour DNA, PCR =&#x02009;polymerase chain reaction, qPCR =&#x02009;quantitative PCR, MSP =&#x02009;methylation specific PCR, qMSP =&#x02009;quantitative methylation specific PCR, ddMethyLight PCR =&#x02009;droplet digital MethyLight PCR, MCTA-Seq =&#x02009;methylated CpG tandem amplification and sequencing, AS-qPCR =&#x02009;allele specific-quantitative PCR, NGS =&#x02009;next-generation sequencing, QuARTS =&#x02009;quantitative allele-specific real-time target and signal amplification, RT-qPCR =&#x02009;reverse transcription-quantitative PCR</p></caption><graphic xlink:href="384_2025_4904_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Performance (sensitivity =&#x02009;sens &#x00026; specificity =&#x02009;spec) of reported biomarker panels for colorectal cancer (CRC) and advanced precancerous lesions (APL)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Biomarkers</th><th align="left">ctDNA source</th><th align="left">Method</th><th align="left" colspan="2">CRC panel</th><th align="left" colspan="4">Stage sensitivity, %</th><th align="left">APL sensitivity,% (n)</th></tr><tr><th align="left"/><th align="left"/><th align="left"/><th align="left"/><th align="left">Sens, % (n)</th><th align="left">Spec, % (n)</th><th align="left">I</th><th align="left">II</th><th align="left">III</th><th align="left">IV</th><th align="left"/></tr></thead><tbody><tr><td align="left">Ahlquist 2000 [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">APC, Bat-26, KRAS, L-DNA, p53</td><td align="left">Stool</td><td align="left">PCR</td><td char="." align="char">91.0 (20/22)</td><td char="." align="char">93.0 (26/28)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">82.0 (9/11)</td></tr><tr><td align="left">Ahlquist 2012 [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">KRAS, mBMP3, mNDRG4, mTFPI2, mVIM, &#x003b2;-actin, Haemoglobin</td><td align="left">Stool</td><td align="left">QuARTS</td><td char="." align="char">85.0 (214/252</td><td char="." align="char">89.0 (261/293)</td><td align="left">84.0</td><td align="left">80.0</td><td align="left">95.0</td><td align="left">69.0</td><td align="left">54.0 (72/133)</td></tr><tr><td align="left">Bach 2021 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">mSDC2, mSEPT9</td><td align="left">Urine</td><td align="left">qMSP</td><td char="." align="char">70.0 (64/92)</td><td char="." align="char">86.0 (54/63)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Bartak 2017 [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left">mPRIMA1, mSDC2, mSFRP1, mSFRP2</td><td align="left">Plasma</td><td align="left">MethyLight PCR</td><td char="." align="char">91.5 (43/47)</td><td char="." align="char">97.3 (36/37)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">89.2 (33/37)</td></tr><tr><td align="left">Bosch 2019 [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (MT-sDNA)</td><td align="left">Stool</td><td align="left">PCR</td><td char="." align="char">85.7 (6/7)</td><td char="." align="char">89.1 (791/888)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">47.8 (44/92)</td></tr><tr><td align="left">Brenne 2023 [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">mBMP3, mFLI1, mIKZF1, mNPTX2, mSFRP1, mSFRP2, mSLC8 A1, mVIM</td><td align="left">Plasma</td><td align="left">MSP</td><td char="." align="char">43.0 (31/72)</td><td char="." align="char">86.0 (61/71)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Cassinotti 2012 [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">mCYCD2, mHIC1, mPAX5, mRASSF1 A, mRB1, mSRBC</td><td align="left">Plasma</td><td align="left">PCR</td><td char="." align="char">83.7 (&#x02212;/30)</td><td char="." align="char">67.9 (&#x02212;/30)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">&#x02009;&#x02212; [54.6 (&#x02212;/30)<sup>a</sup>]</td></tr><tr><td align="left">Chen Y 2019 [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">mSDC2, mSEPT9 (ColoDefense)</td><td align="left">Serum</td><td align="left">qPCR</td><td char="." align="char">86.5 (96/111)</td><td char="." align="char">92.1 (105/114)</td><td align="left">69.2</td><td align="left">85.7</td><td align="left">89.7</td><td align="left">100.0</td><td align="left">-</td></tr><tr><td align="left">Cheng 2021 [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left">mADHFE1, mPPP2R5 C, mSDC2</td><td align="left">Stool</td><td align="left">qMSP</td><td char="." align="char">84.6 (11/13)</td><td char="." align="char">92.3 (12/13)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">&#x02009;&#x02212; [75.0 (3/4)<sup>a</sup>]</td></tr><tr><td align="left">Cho 2021 [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left">mFAM123 A, mGLI3, mPPP1R16B, mSLIT3, mTMEM90B</td><td align="left">Plasma</td><td align="left">ddMethyLight PCR</td><td char="." align="char">57.3 (56/97)</td><td char="." align="char">95.0 (57/60)</td><td align="left">35.3</td><td align="left">54.2</td><td align="left">45.5</td><td align="left">95.7</td><td align="left">-</td></tr><tr><td align="left">Ciarloni 2016 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">29 gene panel, CEA, CYFRA21-1</td><td align="left">Plasma</td><td align="left">RT-qPCR</td><td char="." align="char">78.1 (57/73)</td><td char="." align="char">92.2 (83/90)</td><td align="left" colspan="2">60.6</td><td align="left" colspan="2">92.5</td><td align="left">52.3 (34/65)</td></tr><tr><td align="left">Fan 2023 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (ColoClear MT-sDNA), CEA, 6 genera of gut microbiota</td><td align="left">Stool</td><td align="left">RT-qPCR</td><td char="." align="char">98.1 (&#x02212;/54)</td><td char="." align="char">92.3 (&#x02212;/51)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Gagrat 2024 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">mLASS4, mLRRC4, mPPP2R5 C, mZDHHC1, Haemoglobin</td><td align="left">Stool</td><td align="left">QuARTS</td><td char="." align="char">95.2 (&#x02212;/112)</td><td char="." align="char">89.8 (&#x02212;/176)</td><td align="left">93.9</td><td align="left">94.7</td><td align="left">100.0</td><td align="left">100.0</td><td align="left">57.2 (&#x02212;/98)</td></tr><tr><td align="left">He 2010 [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">mALX4, mSEPT9, mTMEFF2</td><td align="left">Plasma</td><td align="left">MethyLight PCR</td><td char="." align="char">81.0 (147/182)</td><td char="." align="char">90.0 (153/170)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Imperiale 2014 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (Cologuard MT-sDNA)</td><td align="left">Stool</td><td align="left">PCR</td><td char="." align="char">92.3 (60/65)</td><td char="." align="char">89.8 (4002/4457)</td><td align="left" colspan="3">93.3</td><td align="left">-</td><td align="left">42.4 (321/757)</td></tr><tr><td align="left">Imperiale 2024 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">mLASS4, mLRRC4, mPPP2R5 C, mZDHHC1, Haemoglobin</td><td align="left">Stool</td><td align="left">RT-qPCR</td><td char="." align="char">93.0 (53/57)</td><td char="." align="char">88.5 (6214/7022)</td><td align="left">92.0</td><td align="left">100.0</td><td align="left">83.3</td><td align="left">75.0</td><td align="left">48.4 (282/583)</td></tr><tr><td align="left">Itzkowitz 2007 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">mVIM, DIA (DNA Integrity Assay)</td><td align="left">Stool</td><td align="left">MSP</td><td char="." align="char">87.5 (35/40)</td><td char="." align="char">82.0 (100/122)</td><td align="left">75.0</td><td align="left">90.0</td><td align="left">94.1</td><td align="left">80.0</td><td align="left">-</td></tr><tr><td align="left">Jiang 2022 [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">mPAX8, mRASSF1, mSFRP2, Haemoglobin/FIT</td><td align="left">Stool</td><td align="left">MSP</td><td char="." align="char">80.0 (100/125)</td><td char="." align="char">93.6 (117/125)</td><td align="left" colspan="3">73.2</td><td align="left">88.9</td><td align="left">-</td></tr><tr><td align="left">Kranenbarg 2021 [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">mAKR1B1, mCOL6 A2, mMAL, mTMEFF2, mZNF671</td><td align="left">Plasma</td><td align="left">MSP</td><td char="." align="char">-</td><td char="." align="char">100 (20/20)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">100.0</td><td align="left">-</td></tr><tr><td align="left">Lee 2009 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">mAPC, mMGMT, mRASSF2 A, mWIF1</td><td align="left">Plasma</td><td align="left">MSP</td><td char="." align="char">86.5 (&#x02212;/243)</td><td char="." align="char">92.1 (&#x02212;/276)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">&#x02009;&#x02212; [74.6 (&#x02212;/64)<sup>a</sup>]</td></tr><tr><td align="left">Li 2019 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">80 marker panel (including mSEPT9, mIKZF1)</td><td align="left">Plasma</td><td align="left">MCTA-Seq</td><td char="." align="char">77.0 (&#x02212;/147)</td><td char="." align="char">90.0 (&#x02212;/136)</td><td align="left">65.0</td><td align="left">76.0</td><td align="left" colspan="2">81.0</td><td align="left">-</td></tr><tr><td align="left">Lidgard 2013 [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (MT-sDNA)</td><td align="left">Stool</td><td align="left">QuARTS</td><td char="." align="char">98.0 (91/93)</td><td char="." align="char">90.0 (716/796)</td><td align="left">95.0</td><td align="left">100.0</td><td align="left">97.0</td><td align="left">100.0</td><td align="left">57.0 (65/114)</td></tr><tr><td align="left">Lin 2022 [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left">APC, BRAF, KRAS, mSDC2, mSFRP2</td><td align="left">Stool</td><td align="left">qMSP</td><td char="." align="char">88.6 (93/105)</td><td char="." align="char">88.4 (84/95)</td><td align="left">88.9</td><td align="left">83.3</td><td align="left">88.5</td><td align="left">100.0</td><td align="left">75.0 (69/92)</td></tr><tr><td align="left">Liu 2024 [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left">mSDC2, mSEPT9, mVIM</td><td align="left">Stool</td><td align="left">Multiplex PCR</td><td char="." align="char">91.4 (&#x02212;/14)</td><td char="." align="char">100.0 (19/19)</td><td align="left">100.0</td><td align="left">91.3</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Lohsiriwat 2024 [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left">mADHFE1, mSDC2, mPPP2R5 C</td><td align="left">Stool</td><td align="left">qMSP</td><td char="." align="char">91.5 (43/47)</td><td char="." align="char">90.3 (205/227)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">29.4 (5/17)</td></tr><tr><td align="left">Lu 2014 [<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left">mGATA4/5, mNDRG4, mSFRP2, mVIM</td><td align="left">Stool</td><td align="left">MSP</td><td char="." align="char">96.4 (54/56)</td><td char="." align="char">65.0 (26/40)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Ma 2022 [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left">mNDRG4, mSDC2, mTFPI2, mWIF1 (ColoCaller)</td><td align="left">Stool</td><td align="left">qMSP</td><td char="." align="char">94.9 (37/39)</td><td char="." align="char">98.1 (105/107)</td><td align="left">88.9</td><td align="left">93.8</td><td align="left">100.0</td><td align="left">100.0</td><td align="left">100.0 (6/6)</td></tr><tr><td align="left">Melotte 2015 [<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left">mFOXE1, mSYNE1</td><td align="left">Plasma</td><td align="left">qMSP</td><td char="." align="char">58.0 (38/66)</td><td char="." align="char">91.0 (219/240)</td><td align="left">37.0</td><td align="left">87.0</td><td align="left">55.0</td><td align="left">100.0</td><td align="left">-</td></tr><tr><td align="left">Mo 2021 [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left">BRAF, KRAS, PI3 KCA, mBMP3, mNDRG4, mSEPT9, FIT, Fusobacterium nucleatum, Parvimonas micra</td><td align="left">Stool</td><td align="left">NGS, qPCR</td><td char="." align="char">81.5 (88/108)</td><td char="." align="char">94.4 (34/36)</td><td align="left">60.0</td><td align="left">84.6</td><td align="left">91.9</td><td align="left">75.0</td><td align="left">- [27.8 (5/18)<sup>a</sup>]</td></tr><tr><td align="left">Mu 2020 [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left">KRAS, mBMP3, mNDRG4, &#x003b2;-actin, Haemoglobin/FIT (ColoClear MT-sDNA)</td><td align="left">Stool</td><td align="left">RT-qPCR</td><td char="." align="char">97.5 (198/203)</td><td char="." align="char">89.1 (384/431)</td><td align="left">100.0</td><td align="left">96.5</td><td align="left">100.0</td><td align="left">94.1</td><td align="left">53.1 (26/49)</td></tr><tr><td align="left">Park 2017 [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td align="left">mBMP3, mNDRG4, mSFRP2, mTFPI2</td><td align="left">Stool</td><td align="left">MSP</td><td char="." align="char">94.3 (33/35)</td><td char="." align="char">55.0 (22/40)</td><td align="left" colspan="2">88.2</td><td align="left" colspan="2">100.0</td><td align="left">72.2 (26/36)</td></tr><tr><td align="left">Pasha 2019 [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">mRUNX3, mSFRP1, CEA</td><td align="left">Stool</td><td align="left">MSP</td><td char="." align="char">84.7 (72/85)</td><td char="." align="char">67.5 (27/40)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Rasmussen 2017 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td align="left">mALX4, mBMP3, mNPTX2, mRARB, mSDC2, mSEPT9, mVIM, female, age &#x0003e;&#x02009;66</td><td align="left">Plasma</td><td align="left">MSP</td><td char="." align="char">90.7 (175/193)</td><td char="." align="char">72.5 (74/102)</td><td align="left" colspan="2">88.7</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Sun 2019 [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left">KRAS, mSDC2, mSFRP2, Haemoglobin</td><td align="left">Stool</td><td align="left">MethyLight PCR, AS-qPCR</td><td char="." align="char">91.4 (96/105)</td><td char="." align="char">86.1 (93/108)</td><td align="left">87.5</td><td align="left">100.0</td><td align="left">-</td><td align="left">-</td><td align="left">60.0 (12/20)</td></tr><tr><td align="left">Tagore 2003 [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left">APC, BAT-26, KRAS, p53, DIA (DNA Integrity Assay)</td><td align="left">Stool</td><td align="left">PCR</td><td char="." align="char">63.5 (33/52)</td><td char="." align="char">96.2 (204/212)</td><td align="left">75.0</td><td align="left">66.7</td><td align="left">41.7</td><td align="left">50.0</td><td align="left">57.1 (16/28)</td></tr><tr><td align="left">Wang 2021 [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left">mBMP3, mNDRG4, mSDC2, Haemoglobin (sDNA-FOBT)</td><td align="left">Stool</td><td align="left">qPCR</td><td char="." align="char">85.4 (41/48)</td><td char="." align="char">92 (46/50)</td><td align="left">71.4</td><td align="left">88.9</td><td align="left">80.0</td><td align="left">100.0</td><td align="left">&#x02009;&#x02212; [85.7 (6/7)<sup>a</sup>]</td></tr><tr><td align="left">Xu 2021 [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td align="left">mBCAT1, mSDC2, mSEPT9, CEA, Haemoglobin/FIT</td><td align="left">Plasma, Stool</td><td align="left">RT-qPCR</td><td char="." align="char">84.6 (&#x02212;/104)</td><td char="." align="char">95.4 (&#x02212;/&#x02212;)</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Yang 2020 [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td align="left">KRAS, mNDRG4, mSDC2, mTFPI2, &#x003b2;-actin</td><td align="left">Stool</td><td align="left">qMSP</td><td char="." align="char">90.0 (45/50)</td><td char="." align="char">94.0 (47/50)</td><td align="left" colspan="3">91.9</td><td align="left">84.6</td><td align="left">70.6 (36/51)</td></tr><tr><td align="left">Young 2021 [<xref ref-type="bibr" rid="CR74">74</xref>]</td><td align="left">mBCAT1, mIKZF1, mIRF4</td><td align="left">Plasma</td><td align="left">qPCR</td><td char="." align="char">73.9 (136/184)</td><td char="." align="char">90.1 (739/820)</td><td align="left">39.0</td><td align="left">87.7</td><td align="left">78.4</td><td align="left">84.8</td><td align="left">15.7 (53/337)</td></tr><tr><td align="left">Yuan 2016 [<xref ref-type="bibr" rid="CR75">75</xref>]</td><td align="left">mOSMR, mSEPT9</td><td align="left">Plasma</td><td align="left">MethyLight PCR</td><td char="." align="char">77.0 (144/187)</td><td char="." align="char">81.7 (89/109)</td><td align="left" colspan="2">78.1</td><td align="left" colspan="2">76.8</td><td align="left">&#x02009;&#x02212; [28.0 (7/25)<sup>p</sup>]</td></tr><tr><td align="left">Zhang 2014 [<xref ref-type="bibr" rid="CR76">76</xref>]</td><td align="left">mSFRP2, mWIF1</td><td align="left">Stool</td><td align="left">MSP</td><td char="." align="char">81.3 (39/48)</td><td char="." align="char">96.7 (29/30)</td><td align="left">85.7</td><td align="left">80.0</td><td align="left">71.4</td><td align="left">100.0</td><td align="left">80.0 (12/15)</td></tr><tr><td align="left">Zhang 2021 [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left">mSDC2, mTFPI2</td><td align="left">Stool</td><td align="left">qMSP</td><td char="." align="char">93.4 (57/61)</td><td char="." align="char">94.3 (50/53)</td><td align="left" colspan="2">92.3</td><td align="left" colspan="2">94.3</td><td align="left">&#x02009;&#x02212; [81.3 (13/16)<sup>a</sup>]</td></tr><tr><td align="left">Zhao 2019 [<xref ref-type="bibr" rid="CR78">78</xref>]</td><td align="left">mSDC2, mSEPT9 (ColoDefense)</td><td align="left">Plasma</td><td align="left">qMSP</td><td char="." align="char">88.9 (104/117)</td><td char="." align="char">92.8 (154/166)</td><td align="left">80.0</td><td align="left">90.0</td><td align="left">89.5</td><td align="left">100.0</td><td align="left">47.8 (11/23)</td></tr><tr><td align="left">Zhao 2021 [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left">mSDC2, mSFRP2 (SpecColon)</td><td align="left">Stool</td><td align="left">qPCR</td><td char="." align="char">89.7 (52/58)</td><td char="." align="char">89.5 (34/38)</td><td align="left">88.9</td><td align="left">93.3</td><td align="left">83.3</td><td align="left">100.0</td><td align="left">61.5 (8/13)</td></tr></tbody></table><table-wrap-foot><p><italic>ctDNA source</italic>, circulating tumour DNA source; <italic>PCR</italic>, polymerase chain reaction; <italic>qPCR</italic>, quantitative PCR; <italic>MSP</italic>, methylation specific PCR; <italic>qMSP</italic>, quantitative methylation specific PCR; <italic>ddMethyLight PCR</italic>, droplet digital MethyLight PCR; <italic>MCTA-Seq</italic>, methylated CpG tandem amplification and sequencing; <italic>AS-qPCR</italic>, allele specific-quantitative PCR; <italic>NGS</italic>, next-generation sequencing; <italic>QuARTS</italic>, quantitative allele-specific real-time target and signal amplification; <italic>RT-qPCR</italic>, reverse transcription-quantitative PCR; <italic>a</italic>, adenoma data; <italic>p</italic>, polyp data; &#x02018;&#x02019;- &#x02018;&#x02019;, not specified/cannot be inferred from data; <italic>n</italic>, sample; <italic>m</italic>, methylated</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Panel performance for colorectal cancer and advanced precancerous lesions</title><p id="Par25">From the 44 studies, the CRC overall sensitivities ranged from 43.0 to 98.1% and the specificities from 55.0 to 100%. With regards to the APL, sensitivities amongst studies ranged from 15.7 to 100%. Furthermore, the majority of CRC stage sensitivities (I<bold>&#x02013;</bold>IV) for each study showed an increase with higher disease stages. The sensitivities ranged from 35.3 to 100% for stage I, 54.2<bold>&#x02013;</bold>100% for stage II, 41.7<bold>&#x02013;</bold>100% for stage III, and 50<bold>&#x02013;</bold>100% for stage IV. The biomarker panel performance of each individual study is summarised in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, along with the respective outcome measures for the panel&#x02019;s accuracy for CRC and APL detection.</p><sec id="Sec15"><title>KRAS, mBMP3, mNDRG4, and haemoglobin panels (7 studies)</title><p id="Par26">Several reported studies using variants of the Cologuard&#x000ae; stool test in an attempt to replicate or improve the biomarker panel. Six studies utilised the 4-biomarker strategy of KRAS, methylated BMP3, methylated NDRG4, and faecal haemoglobin (including &#x003b2;-actin as reference gene) with stool samples, showing overall CRC sensitivities of 81.5&#x02013;98.1% with specificities of 89.0&#x02013;94.4% [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. The biomarker panels detected APLs with moderate performance (42.4&#x02013;57.0%). The most promising biomarker combination from this cohort remains the classic 4-biomarker panel with the highest performance achieved by Lidgard et al. (case&#x02013;control design) [<xref ref-type="bibr" rid="CR57">57</xref>], with CRC sensitivity and specificity of 98% (91/93) and 90% (716/796), respectively, and an APL sensitivity of 57% (65/114). For Stage I to IV CRC, sensitivities were 95%, 100%, 97%, and 100%. Attempts to improve the current 4-biomarker panel by adding further methylated genes by Alquist et al. [<xref ref-type="bibr" rid="CR39">39</xref>] and even stool bacteria level detection (microbial dysbiosis) by Mo et al. [<xref ref-type="bibr" rid="CR64">64</xref>], proved to be unsuccessful in increasing the overall performance of the panel in those studies. Despite, this Fan et al. combined the 4-biomarker panel with CEA and 6 genera of gut microbiota, enhancing performance to 98.1% (&#x02212;/53) sensitivity and 92.3% (&#x02212;/51) specificity. However, their findings did not include APLs [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec16"><title>mSDC2 and mSEPT9 panels (6 studies)</title><p id="Par27">The 2-biomarker panel of methylated SDC2 and methylated SEPT9, being another common strategy, was used in isolation by three studies [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR78">78</xref>], while three other studies combined it with additional mutational and/or epigenetic markers [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. The panels achieved overall CRC sensitivities between 70.0&#x02013;91.4% and specificities of 72.5&#x02013;100%, with only Zhao et al. [<xref ref-type="bibr" rid="CR78">78</xref>] reporting an APL sensitivity (47.8%). The 2-biomarker panel of mSDC2 and mSEPT9 is referred commercially as ColoDefense&#x000ae;, and Zhao et al.&#x02019;s study demonstrated the best overall performance out of the cohort with 88.9% (104/117) and 92.8% (154/166) CRC sensitivity and specificity, and a moderate performance of 47.8% (11/23) for APL. For Stage I to IV CRC, sensitivities were 80%, 90%, 89.5%, and 100%. The three studies combining the 2-biomarker panel with other markers [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR72">72</xref>], reported sensitivities of 91.4%, 90.7%, and 84.6%, and specificities of 100%, 72.5%, and 95.4%, respectively, without evaluating accuracy for APL detection. While some combinations improved performance, the variability in findings suggests that, at present, the classic 2-biomarker mSDC2 and mSEPT9 panel remains the most reliable choice for overall CRC detection in the group, particularly as it is the only one to have reported results for APL detection.</p></sec><sec id="Sec17"><title>mSDC2 and mSFRP1/2 panels (4 studies)</title><p id="Par28">High performance was exhibited by a biomarker panel combination including methylated SCD2 with methylated SFRP1 and/or SFRP2, with overall CRC sensitivities of 88.6&#x02013;91.5% and specificities of 86.1&#x02013;97.3%, alongside APL sensitivities of 60.0&#x02013;89.2% [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. The best performing panel including methylated PRIMA1, SDC2, SFRP1, and SFRP2, was reported by Bartak et al. [<xref ref-type="bibr" rid="CR41">41</xref>]. This plasma-based 4-biomarker panel achieved 91.5% (43/47) and 97.3% (36/37) overall CRC sensitivity and specificity, alongside the relatively high APL sensitivity of 89.2% (33/37).</p></sec><sec id="Sec18"><title>mSDC2 and mTFPI2 panels (3 studies)</title><p id="Par29">Three biomarker panels including methylated SCDC2 alongside methylated TFPI2 achieved remarkable performances in terms of their overall CRC sensitivities and specificities which ranged from 90.0 to 94.9% and 94.0&#x02013;98.1% respectively. The APL sensitivities showed promising performance ranging from 70.0&#x02013;100% [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. The ColoCaller, a recent stool-based 4-biomarker panel of methylated NDRG4, SDC2, TFPI2, and WIF1, showed encouraging performance for overall CRC detection with 94.9% (37/39) sensitivity and 98.1% (105/107) specificity. Stage-based detection (I&#x02013;IV) was 88.9%, 93.8%, 100%, and 100%, accordingly. The APL performance was perfect with 100% (6/6) detection rate, the highest accuracy of the cohort, highlighting its early screening potential [<xref ref-type="bibr" rid="CR62">62</xref>]. Another 4-biomarker panel of KRAS, methylated NDRG4, SDC2, and TFPI2 (along with &#x003b2;-actin reference gene), displayed a higher performance when compared to other biomarker combinations, with CRC sensitivities and specificities of 90.0% (45/50) and 94.0% (47/50). However, compared to ColoCaller, its APL sensitivity of 70.6% (36/51) was lower [<xref ref-type="bibr" rid="CR73">73</xref>].</p></sec><sec id="Sec19"><title>mLASS4, mLRRC4, mPPP2R5 C, mZDHHC1, and haemoglobin panels (2 studies)</title><p id="Par30">Two recent biomarker panels incorporating methylated LASS4, LRRC4, PPP2R5 C, ZDHHC1, and Haemoglobin demonstrated strong overall CRC detection, with sensitivities of 93.0&#x02013;95.2% and specificities of 88.5&#x02013;89.8% [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. APL detection was moderate, ranging from 48.4&#x02013;57.2%. The Gagrat et al. panel [<xref ref-type="bibr" rid="CR49">49</xref>] performed best, achieving 95.2% (-/112) CRC sensitivity and 89.8% (-/176) specificity, with CRC stage-based detection (I&#x02013;IV) of 93.9%, 94.7%, 100%, and 100%. Its 57.2% (-/98) APL sensitivity was higher than the 48.4% (282/583) observed in Imperiale et al. [<xref ref-type="bibr" rid="CR51">51</xref>], though both were suboptimal compared to other biomarker combinations.</p></sec><sec id="Sec20"><title>Other panels (5 studies)</title><p id="Par31">A 5-biomarker panel, consisting of the mutational targets APC, Bat-26, KRAS, L-DNA, and p53 by Ahlquist et al., achieved a high performance for overall CRC detection with 91.0% (20/22) sensitivity and 93.0% (26/28) specificity, with an APL detection rate of 82.0% (9/11) [<xref ref-type="bibr" rid="CR38">38</xref>]. Multi-gene panels of 20 +&#x02009;biomarkers was assessed by 2 studies. Ciaroloni et al. used a panel with 29 genes, CEA and CYFRA21-1 and Li et al. an 80-marker panel including methylated SEPT9 and IKZF1, achieving a similar performance for CRC detection with sensitivities of 78.1% and 77.0%, and specificities of 92.2% and 90.0%, respectively. Despite the specificities above 90%, sensitivities are inferior compared to other potentially more cost-effective candidate panels with less biomarkers [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Furthermore, a 4-biomarker panel was the only one combining methylated BMP3, NDRG4, SDC2 with FOBT (and not FIT), achieving a moderately good performance for detection of CRC, 85.4% sensitivity and 92% specificity, and all adenomas (85.7% sensitivity). Unfortunately, as with several other studies, the reporting style could not distinguish specific detection rates for advanced precancerous lesions, but only for all adenomas or polyps in general [<xref ref-type="bibr" rid="CR71">71</xref>]. Lastly, a 2-biomarker panel by Zhang et al. with methylated SFRP2 and WIFI1 demonstrated the fourth highest detection rate for APL (80%, 12/15) with similar sensitivity for overall CRC detection 81.3% (39/48) [<xref ref-type="bibr" rid="CR76">76</xref>].</p></sec></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par32">This review systematically assessed genetic and epigenetic biomarker panels using ctDNA from blood, stool, or urine, identifying promising combinations for CRC and APL detection. While several panels displayed satisfactory performance for overall CRC detection, few excelled in both CRC and APL detection, notably those combining mSDC2 with mSFRP1/2 (CRC: 91.5%/97.3%, APL: 89.2%) or mTFPI2 (CRC: 94.9%/98.1%, APL: 100%), and a 5-biomarker panel (APC, Bat-26, KRAS, L-DNA, p53; CRC: 91.0%/93.0%, APL: 82.0%). Panels such as Cologuard (including KRAS, mBMP3, mNDRG4, FIT) and mSEPT9 combinations had suboptimal APL sensitivities (up to 57% and 47.8, respectively).</p><p id="Par33">The heterogeneous nature of CRC, involving various genetic and epigenetic alterations, necessitates the exploration of combinatory biomarker panels for rapid detection of malignant neoplasms and advanced precancerous lesions using liquid biopsies. High-sensitivity and high-specificity screening methods are crucial due to the morbidity and mortality associated with late CRC diagnosis, as well as the low uptake and drawbacks of available invasive or semi-invasive methods [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Additionally, the limited potential of currently approved biomarker panels for detecting advanced precancerous lesions, underscores the need to summarise the performance of kits in the literature [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par34">The highest overall performing panels in terms of both CRC and APL detection consisted of methylated SDC2 in combination with methylated SFRP1/2 or TFPI2. A plasma-based 4-biomarker panel by Bartak et al. [<xref ref-type="bibr" rid="CR41">41</xref>] including methylated PRIMA1, SDC2, SFRP1, and SFRP2, achieved an excellent overall CRC sensitivity and specificity of 91.5% (43/47) and 97.3% (36/37), along with a promising APL sensitivity of 89.2% (33/37). In contrast, combination of methylated SCD2 with SEPT9 in ColoDefense&#x000ae; panel yielded a high CRC sensitivity and specificity of 88.9% (104/117) and 92.8% (154/166), however with a moderate APL detection accuracy of 47.8% (11/23) [<xref ref-type="bibr" rid="CR78">78</xref>]. Nevertheless, these findings clash with suggestions that combination panels with methylated SEPT9 have the highest potential for early CRC detection, as certain non-mSEPT9 combinations show superior performance for both APL and CRC detection [<xref ref-type="bibr" rid="CR80">80</xref>]. Similarly, the panel variants of 4-biomarker stool test Cologuard (KRAS, mBMP3, mNDRG4, FIT) managed to achieve performances above 90% for overall CRC sensitivity and specificity, with suboptimal performances for APL detection, compared to other options, with the highest detection rate of 57% (65/114) by Lidgard et al. [<xref ref-type="bibr" rid="CR57">57</xref>]. The performance data suggest that Cologuard combinations may not be the optimal diagnostic choice for APL. Similarly, FOBTs alone have even less diagnostic potential for APLs due to their poor sensitivity, but despite this their cost-effectiveness and lack of currently approved alternatives renders them usable in non-colonoscopy compliant populations for detection of advanced colorectal neoplasms. Importantly, some form of screening is preferable to none to identify cases in the early asymptomatic stage.</p><p id="Par35">Another example of a high-performance panel is, ColoCaller, a recently reported stool-based 4-biomarker panel of methylated NDRG4, SDC2, TFPI2, and WIF1, exhibiting excellent performance for overall CRC (94.9% sensitivity, 37/39 and 98.1% specificity, 105/107) and APL detection (100% sensitivity, 6/6) [<xref ref-type="bibr" rid="CR62">62</xref>]. Similarly, two other biomarker panels in the 2-biomarker combination cohort of methylated SDC2 and TFPI2 exhibited CRC detection rates of 90% and over, with 70.6% APL detection for Yang et al. [<xref ref-type="bibr" rid="CR73">73</xref>] and 81.3% all adenomas detection (no APL-specific data) for Zhang et al. [<xref ref-type="bibr" rid="CR77">77</xref>], emphasising the strong diagnostic capability of this biomarker combination. Lastly, a 5-mutational biomarker panel (APC, Bat-26, KRAS, L-DNA, and p53) achieved slightly improved sensitivity for APL at 82.0%, with high performance for overall CRC detection (91% sensitivity, 93% specificity), highlighting its diagnostic potential [<xref ref-type="bibr" rid="CR38">38</xref>]. The panel consists exclusively of genetic biomarkers, and there have been no follow studies or updated panel candidates to re-assess its accuracy in the last two decades, apart from Tagore et al. [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par36">Several studies have focused on ctDNA sources and their implications. Stool ctDNA has been utilised in early diagnostics, as the sample is physically more proximal to the colorectal disease compared to blood samples, with early-stage lesions developing predominantly within the mucosa and shedding into the colonic lumen. However, stool ctDNA extraction can be challenging due to low ctDNA concentrations compared to surrounding microbial DNA in stool samples [<xref ref-type="bibr" rid="CR27">27</xref>]. Similarly, challenges arise with plasma, as it has a lower ctDNA-to-total cell-free DNA ratio, originating from clonal haematopoiesis, which is affected by age and radiotherapy, creating background noise [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. Additionally, plasma ctDNA can suffer from improper separation, prolonged storage, and repeated freeze&#x02013;thaw cycles, affecting DNA integrity mainly in retrospective studies [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Large-scale studies should aim for prospective sample collection with minimal storage prior to plasma analysis.</p><p id="Par37">Apart from ctDNA concentrations and storage implications, patient preference and compliance can influence the choice of ctDNA source. Biomarker panels generally increase colorectal cancer screening compliance in previously non-compliant populations. Specifically, blood-based testing (mSEPT9) was preferred by 93.5% of participants in underserved populations, compared to 6.5% for stool-based methods (FIT) [<xref ref-type="bibr" rid="CR84">84</xref>]. Testing rates increased from 12.6% with FIT to 93.5% with the blood test, suggesting that convenience and same-day sample collection align better with patient expectations. This strong preference for blood-based panels over stool-based ones indicates a potential strategy for improved adherence and cost-effective public health screening.</p><p id="Par38">Limitations of the included studies primarily revolve around study design and methodology. Most were cross-sectional case&#x02013;control studies with small sample sizes, and only a few were larger cohort studies, such as Imperiale et al. [<xref ref-type="bibr" rid="CR31">31</xref>]. No study had a randomised design to assess the clinical benefit of their biomarker panel. According to QUADAS-2, many studies lacked detailed information on patient selection (e.g., sampling method, recruitment timing), potentially introducing bias and uncertainty about the true study design. Inconsistencies in reporting panel performance, particularly for APL, were noted, with some studies only reporting on adenomas or polyps or not at all. Additionally, methods for extracting and quantifying ctDNA varied widely with different cut-off points to balance sensitivity and specificity. There are yet no agreed standards for these methods.</p><p id="Par39">While we systematically searched four major databases and performed citation searching, it is possible that some relevant ctDNA panels were not identified due to the nature of study reporting. Most studies included used a cross-sectional case&#x02013;control design with relatively small sample sizes and varied in methodological reporting quality. Cost-effectiveness analysis of ctDNA panels and use of other liquid biopsy markers (e.g., cell-free nucleosomes, miRNAs, CTCs, proteomics) were beyond the scope of our review, yet remain crucial considerations from both an economic and future research perspective. Lastly, heterogeneity in panel types, analysis methods, and population characteristics precluded a meta-analysis.</p></sec><sec id="Sec22"><title>Conclusion</title><p id="Par40">This review identified high-performance ctDNA biomarker panels with exceptional diagnostic accuracy for both CRC and APL, highlighting their potential for public health screening. The highest APL detection rates were observed in panels including mSDC2 with mSFRP1/2 or mTFPI2, as well as a five-biomarker mutational panel targeting APC, Bat-26, KRAS, L-DNA, and p53. Importantly, Cologuard and variant panels incorporating KRAS, mBMP3, mNDRG4, FIT, and combinations including mSEPT9, exhibited suboptimal APL sensitivity. Future research should prioritise large-scale, cross-sectional cohort or randomised studies to validate proposed ctDNA panels for clinical use. Additionally, improved study reporting is essential, including detailed methodologies with chronological information and consistent data presentation, as illustrated in our tables, to enhance research quality and facilitate data aggregation for future reviews and meta-analyses.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Georgios Alampritis and Sarah Nohelia Thoukididou contributed equally.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contribution</title><p>GA, SNT and CS conceived the study. GA and ST performed the literature search, with disagreements adjudicated by CS. GA and SNT extracted and analysed the data. GA wrote the first draft of the manuscript. SNT and CS reviewed and edited the first draft of the manuscript. MR, PG and MK reviewed later drafts and provided critical appraisal.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data supporting the study are available from the corresponding author on reasonable request via e-mail.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par41">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/CAAC.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209&#x02013;249. 10.3322/CAAC.21660<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Bray F, Soerjomataram I (2015) The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. Disease Control Priorities, 3rd Edition vol 3, Cancer, pp 23&#x02013;44. 10.1596/978-1-4648-0349-9_CH2</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>MM</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>A global view on cancer incidence and national levels of the human development index</article-title><source>Int J Cancer</source><year>2016</year><volume>139</volume><fpage>2436</fpage><lpage>2446</lpage><pub-id pub-id-type="doi">10.1002/IJC.30382</pub-id><pub-id pub-id-type="pmid">27522007</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Fidler MM, Soerjomataram I, Bray F (2016) A global view on cancer incidence and national levels of the human development index. Int J Cancer 139:2436&#x02013;2446. 10.1002/IJC.30382<pub-id pub-id-type="pmid">27522007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Goding Sauer</surname><given-names>A</given-names></name><name><surname>Fedewa</surname><given-names>SA</given-names></name><name><surname>Butterly</surname><given-names>LF</given-names></name><name><surname>Anderson</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Colorectal cancer statistics, 2020</article-title><source>CA Cancer J Clin</source><year>2020</year><volume>70</volume><fpage>145</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.3322/CAAC.21601</pub-id><pub-id pub-id-type="pmid">32133645</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145&#x02013;164. 10.3322/CAAC.21601<pub-id pub-id-type="pmid">32133645</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>BK</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Kohler</surname><given-names>BA</given-names></name><name><surname>Eheman</surname><given-names>C</given-names></name><name><surname>Zauber</surname><given-names>AG</given-names></name><name><surname>Anderson</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Annual report to the nation on the status of cancer, 1975&#x02013;2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates</article-title><source>Cancer</source><year>2010</year><volume>116</volume><fpage>544</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1002/CNCR.24760</pub-id><pub-id pub-id-type="pmid">19998273</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN et al (2010) Annual report to the nation on the status of cancer, 1975&#x02013;2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544&#x02013;573. 10.1002/CNCR.24760<pub-id pub-id-type="pmid">19998273</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Schreuders</surname><given-names>EH</given-names></name><name><surname>Ruco</surname><given-names>A</given-names></name><name><surname>Rabeneck</surname><given-names>L</given-names></name><name><surname>Schoen</surname><given-names>RE</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name><name><surname>Young</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Colorectal cancer screening: a global overview of existing programmes</article-title><source>Gut</source><year>2015</year><volume>64</volume><fpage>1637</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1136/GUTJNL-2014-309086</pub-id><pub-id pub-id-type="pmid">26041752</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJY, Young GP et al (2015) Colorectal cancer screening: a global overview of existing programmes. Gut 64:1637&#x02013;1649. 10.1136/GUTJNL-2014-309086<pub-id pub-id-type="pmid">26041752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Weber</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Global patterns and trends in colorectal cancer incidence in young adults</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>2179</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1136/GUTJNL-2019-319511</pub-id><pub-id pub-id-type="pmid">31488504</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Siegel RL, Torre LA, Soerjomataram I, Hayes RB, Bray F, Weber TK et al (2019) Global patterns and trends in colorectal cancer incidence in young adults. Gut 68:2179&#x02013;2185. 10.1136/GUTJNL-2019-319511<pub-id pub-id-type="pmid">31488504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Vuik</surname><given-names>FER</given-names></name><name><surname>Nieuwenburg</surname><given-names>SAV</given-names></name><name><surname>Bardou</surname><given-names>M</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>Dinis-Ribeiro</surname><given-names>M</given-names></name><name><surname>Bento</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>1820</fpage><lpage>1836</lpage><pub-id pub-id-type="doi">10.1136/GUTJNL-2018-317592</pub-id><pub-id pub-id-type="pmid">31097539</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Vuik FER, Nieuwenburg SAV, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ et al (2019) Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 68:1820&#x02013;1836. 10.1136/GUTJNL-2018-317592<pub-id pub-id-type="pmid">31097539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>AMD</given-names></name><name><surname>Fontham</surname><given-names>ETH</given-names></name><name><surname>Church</surname><given-names>TR</given-names></name><name><surname>Flowers</surname><given-names>CR</given-names></name><name><surname>Guerra</surname><given-names>CE</given-names></name><name><surname>LaMonte</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><fpage>250</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.3322/CAAC.21457</pub-id><pub-id pub-id-type="pmid">29846947</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ et al (2018) Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin 68:250&#x02013;281. 10.3322/CAAC.21457<pub-id pub-id-type="pmid">29846947</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Mik</surname><given-names>M</given-names></name><name><surname>Berut</surname><given-names>M</given-names></name><name><surname>Dziki</surname><given-names>L</given-names></name><name><surname>Trzcinski</surname><given-names>R</given-names></name><name><surname>Dziki</surname><given-names>A</given-names></name></person-group><article-title>Right- and left-sided colon cancer &#x02013; clinical and pathological differences of the disease entity in one organ</article-title><source>Arch Med Sci</source><year>2017</year><volume>13</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.5114/AOMS.2016.58596</pub-id><pub-id pub-id-type="pmid">28144267</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Mik M, Berut M, Dziki L, Trzcinski R, Dziki A (2017) Right- and left-sided colon cancer &#x02013; clinical and pathological differences of the disease entity in one organ. Arch Med Sci 13:157. 10.5114/AOMS.2016.58596<pub-id pub-id-type="pmid">28144267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Ulanja</surname><given-names>MB</given-names></name><name><surname>Rishi</surname><given-names>M</given-names></name><name><surname>Beutler</surname><given-names>BD</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Patterson</surname><given-names>DR</given-names></name><name><surname>Gullapalli</surname><given-names>N</given-names></name><etal/></person-group><article-title>Colon cancer sidedness, presentation, and survival at different stages</article-title><source>J Oncol</source><year>2019</year><volume>2019</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2019/4315032</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Ulanja MB, Rishi M, Beutler BD, Sharma M, Patterson DR, Gullapalli N et al (2019) Colon cancer sidedness, presentation, and survival at different stages. J Oncol 2019:1&#x02013;12. 10.1155/2019/4315032</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Fedewa</surname><given-names>SA</given-names></name><name><surname>Ahnen</surname><given-names>DJ</given-names></name><name><surname>Meester</surname><given-names>RGS</given-names></name><name><surname>Barzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Colorectal cancer statistics, 2017</article-title><source>CA Cancer J Clin</source><year>2017</year><volume>67</volume><fpage>177</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.3322/CAAC.21395</pub-id><pub-id pub-id-type="pmid">28248415</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A et al (2017) Colorectal cancer statistics, 2017. CA Cancer J Clin 67:177&#x02013;193. 10.3322/CAAC.21395<pub-id pub-id-type="pmid">28248415</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Baran</surname><given-names>B</given-names></name><name><surname>Ozupek</surname><given-names>NM</given-names></name><name><surname>Tetik</surname><given-names>NY</given-names></name><name><surname>Acar</surname><given-names>E</given-names></name><name><surname>Bekcioglu</surname><given-names>O</given-names></name><name><surname>Baskin</surname><given-names>Y</given-names></name></person-group><article-title>Difference between left-sided and right-sided colorectal cancer: a focused review of literature</article-title><source>Gastroenterol Res</source><year>2018</year><volume>11</volume><fpage>264</fpage><pub-id pub-id-type="doi">10.14740/GR1062W</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Baran B, Ozupek NM, Tetik NY, Acar E, Bekcioglu O, Baskin Y (2018) Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterol Res 11:264. 10.14740/GR1062W</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Mundade</surname><given-names>R</given-names></name><name><surname>Imperiale</surname><given-names>TF</given-names></name><name><surname>Prabhu</surname><given-names>L</given-names></name><name><surname>Loehrer</surname><given-names>PJ</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name></person-group><article-title>Genetic pathways, prevention, and treatment of sporadic colorectal cancer</article-title><source>Oncoscience</source><year>2014</year><volume>1</volume><fpage>400</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.18632/ONCOSCIENCE.59</pub-id><pub-id pub-id-type="pmid">25594038</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mundade R, Imperiale TF, Prabhu L, Loehrer PJ, Lu T (2014) Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience 1:400&#x02013;6. 10.18632/ONCOSCIENCE.59<pub-id pub-id-type="pmid">25594038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Aaseb&#x000f8;</surname><given-names>K</given-names></name><name><surname>Dragomir</surname><given-names>A</given-names></name><name><surname>Sundstr&#x000f6;m</surname><given-names>M</given-names></name><name><surname>Mezheyeuski</surname><given-names>A</given-names></name><name><surname>Edqvist</surname><given-names>PH</given-names></name><name><surname>Eide</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: a population-based cohort of metastatic colorectal cancer patients</article-title><source>Cancer Med</source><year>2019</year><volume>8</volume><fpage>3623</fpage><lpage>3635</lpage><pub-id pub-id-type="doi">10.1002/CAM4.2205</pub-id><pub-id pub-id-type="pmid">31070306</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Aaseb&#x000f8; K, Dragomir A, Sundstr&#x000f6;m M, Mezheyeuski A, Edqvist PH, Eide GE et al (2019) Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: a population-based cohort of metastatic colorectal cancer patients. Cancer Med 8:3623&#x02013;3635. 10.1002/CAM4.2205<pub-id pub-id-type="pmid">31070306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Koopman</surname><given-names>M</given-names></name><name><surname>Kortman</surname><given-names>GAM</given-names></name><name><surname>Mekenkamp</surname><given-names>L</given-names></name><name><surname>Ligtenberg</surname><given-names>MJL</given-names></name><name><surname>Hoogerbrugge</surname><given-names>N</given-names></name><name><surname>Antonini</surname><given-names>NF</given-names></name><etal/></person-group><article-title>Deficient mismatch repair system in patients with sporadic advanced colorectal cancer</article-title><source>Br J Cancer</source><year>2009</year><volume>100</volume><fpage>266</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/SJ.BJC.6604867</pub-id><pub-id pub-id-type="pmid">19165197</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Koopman M, Kortman GAM, Mekenkamp L, Ligtenberg MJL, Hoogerbrugge N, Antonini NF et al (2009) Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100:266&#x02013;273. 10.1038/SJ.BJC.6604867<pub-id pub-id-type="pmid">19165197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Geiersbach</surname><given-names>KB</given-names></name><name><surname>Samowitz</surname><given-names>WS</given-names></name></person-group><article-title>Microsatellite instability and colorectal cancer</article-title><source>Arch Pathol Lab Med</source><year>2011</year><volume>135</volume><fpage>1269</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.5858/ARPA.2011-0035-RA</pub-id><pub-id pub-id-type="pmid">21970482</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Geiersbach KB, Samowitz WS (2011) Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 135:1269&#x02013;1277. 10.5858/ARPA.2011-0035-RA<pub-id pub-id-type="pmid">21970482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>De Palma</surname><given-names>FDE</given-names></name><name><surname>D&#x02019;argenio</surname><given-names>V</given-names></name><name><surname>Pol</surname><given-names>J</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Maiuri</surname><given-names>MC</given-names></name><name><surname>Salvatore</surname><given-names>F</given-names></name></person-group><article-title>The molecular hallmarks of the serrated pathway in colorectal cancer</article-title><source>Cancers (Basel)</source><year>2019</year><volume>11</volume><fpage>1017</fpage><pub-id pub-id-type="doi">10.3390/CANCERS11071017</pub-id><pub-id pub-id-type="pmid">31330830</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">De Palma FDE, D&#x02019;argenio V, Pol J, Kroemer G, Maiuri MC, Salvatore F (2019) The molecular hallmarks of the serrated pathway in colorectal cancer. Cancers (Basel) 11:1017. 10.3390/CANCERS11071017<pub-id pub-id-type="pmid">31330830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Rustgi</surname><given-names>AK</given-names></name></person-group><article-title>BRAF: a driver of the serrated pathway in colon cancer</article-title><source>Cancer Cell</source><year>2013</year><volume>24</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.06.008</pub-id><pub-id pub-id-type="pmid">23845435</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Rustgi AK (2013) BRAF: a driver of the serrated pathway in colon cancer. Cancer Cell 24:1&#x02013;2. 10.1016/j.ccr.2013.06.008<pub-id pub-id-type="pmid">23845435</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ladabaum</surname><given-names>U</given-names></name><name><surname>Dominitz</surname><given-names>JA</given-names></name><name><surname>Kahi</surname><given-names>C</given-names></name><name><surname>Schoen</surname><given-names>RE</given-names></name></person-group><article-title>Strategies for colorectal cancer screening</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><fpage>418</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1053/J.GASTRO.2019.06.043</pub-id><pub-id pub-id-type="pmid">31394083</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ladabaum U, Dominitz JA, Kahi C, Schoen RE (2020) Strategies for colorectal cancer screening. Gastroenterology 158:418&#x02013;432. 10.1053/J.GASTRO.2019.06.043<pub-id pub-id-type="pmid">31394083</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>K</given-names></name></person-group><article-title>Colorectal cancer development and advances in screening</article-title><source>Clin Interv Aging</source><year>2016</year><volume>11</volume><fpage>967</fpage><pub-id pub-id-type="doi">10.2147/CIA.S109285</pub-id><pub-id pub-id-type="pmid">27486317</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Simon K (2016) Colorectal cancer development and advances in screening. Clin Interv Aging 11:967. 10.2147/CIA.S109285<pub-id pub-id-type="pmid">27486317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Vart</surname><given-names>G</given-names></name><name><surname>Banzi</surname><given-names>R</given-names></name><name><surname>Minozzi</surname><given-names>S</given-names></name></person-group><article-title>Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis</article-title><source>Prev Med (Baltim)</source><year>2012</year><volume>55</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/J.YPMED.2012.05.006</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Vart G, Banzi R, Minozzi S (2012) Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med (Baltim) 55:87&#x02013;92. 10.1016/J.YPMED.2012.05.006</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Liles</surname><given-names>EG</given-names></name><name><surname>Bent</surname><given-names>S</given-names></name><name><surname>Levin</surname><given-names>TR</given-names></name><name><surname>Corley</surname><given-names>DA</given-names></name></person-group><article-title>Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis</article-title><source>Ann Intern Med</source><year>2014</year><volume>160</volume><fpage>171</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.7326/M13-1484</pub-id><pub-id pub-id-type="pmid">24658694</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014) Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 160:171&#x02013;181. 10.7326/M13-1484<pub-id pub-id-type="pmid">24658694</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>HM</given-names></name><name><surname>Jen</surname><given-names>GHH</given-names></name><name><surname>Wang</surname><given-names>YW</given-names></name><name><surname>Fann</surname><given-names>JCY</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Jeng</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers</article-title><source>Gut</source><year>2021</year><volume>70</volume><fpage>2321</fpage><lpage>2329</lpage><pub-id pub-id-type="doi">10.1136/GUTJNL-2020-322545</pub-id><pub-id pub-id-type="pmid">33495268</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Chiu HM, Jen GHH, Wang YW, Fann JCY, Hsu CY, Jeng YC et al (2021) Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers. Gut 70:2321&#x02013;2329. 10.1136/GUTJNL-2020-322545<pub-id pub-id-type="pmid">33495268</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Nordg&#x000e5;rd</surname><given-names>O</given-names></name><name><surname>Tjensvoll</surname><given-names>K</given-names></name><name><surname>Gilje</surname><given-names>B</given-names></name><name><surname>S&#x000f8;reide</surname><given-names>K</given-names></name></person-group><article-title>Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer</article-title><source>Br J Surg</source><year>2018</year><volume>105</volume><fpage>e110</fpage><lpage>e120</lpage><pub-id pub-id-type="doi">10.1002/bjs.10782</pub-id><pub-id pub-id-type="pmid">29341153</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Nordg&#x000e5;rd O, Tjensvoll K, Gilje B, S&#x000f8;reide K (2018) Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. Br J Surg 105:e110&#x02013;e120. 10.1002/bjs.10782<pub-id pub-id-type="pmid">29341153</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Ling</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/S12943-019-1043-X</pub-id><pub-id pub-id-type="pmid">31269959</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ye Q, Ling S, Zheng S, Xu X (2019) Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer 18:114. 10.1186/S12943-019-1043-X<pub-id pub-id-type="pmid">31269959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Tivey</surname><given-names>A</given-names></name><name><surname>Church</surname><given-names>M</given-names></name><name><surname>Rothwell</surname><given-names>D</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name><name><surname>Cook</surname><given-names>N</given-names></name></person-group><article-title>Circulating tumour DNA &#x02014; looking beyond the blood</article-title><source>Nat Rev Clin Oncol</source><year>2022</year><volume>19</volume><issue>9</issue><fpage>600</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00660-y</pub-id><pub-id pub-id-type="pmid">35915225</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Tivey A, Church M, Rothwell D, Dive C, Cook N (2022) Circulating tumour DNA &#x02014; looking beyond the blood. Nat Rev Clin Oncol 19(9):600&#x02013;12. 10.1038/s41571-022-00660-y<pub-id pub-id-type="pmid">35915225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Bettegowda</surname><given-names>C</given-names></name><name><surname>Sausen</surname><given-names>M</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Kinde</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Agrawal</surname><given-names>N</given-names></name><etal/></person-group><article-title>detection of circulating tumor DNA in early- and late-stage human malignancies</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>224ra24</fpage><pub-id pub-id-type="doi">10.1126/SCITRANSLMED.3007094</pub-id><pub-id pub-id-type="pmid">24553385</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24. 10.1126/SCITRANSLMED.3007094<pub-id pub-id-type="pmid">24553385</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Wyatt</surname><given-names>AW</given-names></name><name><surname>Annala</surname><given-names>M</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Beja</surname><given-names>K</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Youngren</surname><given-names>J</given-names></name><etal/></person-group><article-title>Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer</article-title><source>J Natl Cancer Inst</source><year>2017</year><volume>109</volume><fpage>djx118</fpage><pub-id pub-id-type="doi">10.1093/JNCI/DJX118</pub-id><pub-id pub-id-type="pmid">29206995</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J et al (2017) Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst 109:djx118. 10.1093/JNCI/DJX118<pub-id pub-id-type="pmid">29206995</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Peltom&#x000e4;ki</surname><given-names>P</given-names></name></person-group><article-title>Mutations and epimutations in the origin of cancer</article-title><source>Exp Cell Res</source><year>2012</year><volume>318</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/J.YEXCR.2011.12.001</pub-id><pub-id pub-id-type="pmid">22182599</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Peltom&#x000e4;ki P (2012) Mutations and epimutations in the origin of cancer. Exp Cell Res 318:299&#x02013;310. 10.1016/J.YEXCR.2011.12.001<pub-id pub-id-type="pmid">22182599</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Imperiale</surname><given-names>TF</given-names></name><name><surname>Ransohoff</surname><given-names>DF</given-names></name><name><surname>Itzkowitz</surname><given-names>SH</given-names></name><name><surname>Levin</surname><given-names>TR</given-names></name><name><surname>Lavin</surname><given-names>P</given-names></name><name><surname>Lidgard</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Multitarget stool DNA testing for colorectal-cancer screening</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>1287</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1056/nejmoa1311194</pub-id><pub-id pub-id-type="pmid">24645800</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP et al (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287&#x02013;1297. 10.1056/nejmoa1311194<pub-id pub-id-type="pmid">24645800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>McKenzie</surname><given-names>JE</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Boutron</surname><given-names>I</given-names></name><name><surname>Hoffmann</surname><given-names>TC</given-names></name><name><surname>Mulrow</surname><given-names>CD</given-names></name><name><surname>The</surname><given-names>PRISMA</given-names></name><etal/></person-group><article-title>statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2020</year><volume>2021</volume><fpage>372</fpage><pub-id pub-id-type="doi">10.1136/BMJ.N71</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ 2021:372. 10.1136/BMJ.N71</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>DA</given-names></name><name><surname>Rex</surname><given-names>DK</given-names></name><name><surname>Winawer</surname><given-names>SJ</given-names></name><name><surname>Giardiello</surname><given-names>FM</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Levin</surname><given-names>TR</given-names></name></person-group><article-title>Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the us multi-society task force on colorectal cancer</article-title><source>Gastroenterology</source><year>2012</year><volume>143</volume><fpage>844</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2012.06.001</pub-id><pub-id pub-id-type="pmid">22763141</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR (2012) Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the us multi-society task force on colorectal cancer. Gastroenterology 143:844&#x02013;857. 10.1053/j.gastro.2012.06.001<pub-id pub-id-type="pmid">22763141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name></person-group><article-title>The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>17</volume><fpage>1471</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1245/S10434-010-0985-4</pub-id><pub-id pub-id-type="pmid">20180029</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471&#x02013;4. 10.1245/S10434-010-0985-4<pub-id pub-id-type="pmid">20180029</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Mathes</surname><given-names>T</given-names></name><name><surname>Pieper</surname><given-names>D</given-names></name></person-group><article-title>An algorithm for the classification of study designs to assess diagnostic, prognostic and predictive test accuracy in systematic reviews</article-title><source>Syst Rev</source><year>2019</year><volume>8</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/S13643-019-1131-4</pub-id><pub-id pub-id-type="pmid">30606256</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Mathes T, Pieper D (2019) An algorithm for the classification of study designs to assess diagnostic, prognostic and predictive test accuracy in systematic reviews. Syst Rev 8:1&#x02013;8. 10.1186/S13643-019-1131-4<pub-id pub-id-type="pmid">30606256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Whiting</surname><given-names>PF</given-names></name><name><surname>Rutjes</surname><given-names>AWS</given-names></name><name><surname>Westwood</surname><given-names>ME</given-names></name><name><surname>Mallett</surname><given-names>S</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Reitsma</surname><given-names>JB</given-names></name><etal/></person-group><article-title>QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies</article-title><source>Ann Intern Med</source><year>2011</year><volume>155</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-155-8-201110180-00009</pub-id><pub-id pub-id-type="pmid">22007046</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529&#x02013;536. 10.7326/0003-4819-155-8-201110180-00009<pub-id pub-id-type="pmid">22007046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>LJW</given-names></name><name><surname>Melotte</surname><given-names>V</given-names></name><name><surname>Mongera</surname><given-names>S</given-names></name><name><surname>Daenen</surname><given-names>KLJ</given-names></name><name><surname>Coup&#x000e9;</surname><given-names>VMH</given-names></name><name><surname>Van Turenhout</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Multitarget stool DNA test performance in an average-risk colorectal cancer screening population</article-title><source>Am J Gastroenterol</source><year>2019</year><volume>114</volume><fpage>1909</fpage><pub-id pub-id-type="doi">10.14309/AJG.0000000000000445</pub-id><pub-id pub-id-type="pmid">31764091</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Bosch LJW, Melotte V, Mongera S, Daenen KLJ, Coup&#x000e9; VMH, Van Turenhout ST et al (2019) Multitarget stool DNA test performance in an average-risk colorectal cancer screening population. Am J Gastroenterol 114:1909. 10.14309/AJG.0000000000000445<pub-id pub-id-type="pmid">31764091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlquist</surname><given-names>DA</given-names></name><name><surname>Skoletsky</surname><given-names>JE</given-names></name><name><surname>Boynton</surname><given-names>KA</given-names></name><name><surname>Harrington</surname><given-names>JJ</given-names></name><name><surname>Mahoney</surname><given-names>DW</given-names></name><name><surname>Pierceall</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel</article-title><source>Gastroenterology</source><year>2000</year><volume>119</volume><fpage>1219</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1053/gast.2000.19580</pub-id><pub-id pub-id-type="pmid">11054379</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE et al (2000) Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology 119:1219&#x02013;1227. 10.1053/gast.2000.19580<pub-id pub-id-type="pmid">11054379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlquist</surname><given-names>DA</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Domanico</surname><given-names>M</given-names></name><name><surname>Mahoney</surname><given-names>DW</given-names></name><name><surname>Yab</surname><given-names>TC</given-names></name><name><surname>Taylor</surname><given-names>WR</given-names></name><etal/></person-group><article-title>Next-generation stool DNA test accurately detects colorectal cancer and large adenomas</article-title><source>Gastroenterology</source><year>2012</year><volume>142</volume><fpage>248</fpage><pub-id pub-id-type="doi">10.1053/J.GASTRO.2011.10.031</pub-id><pub-id pub-id-type="pmid">22062357</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR et al (2012) Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142:248. 10.1053/J.GASTRO.2011.10.031<pub-id pub-id-type="pmid">22062357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>S</given-names></name><name><surname>Paulis</surname><given-names>I</given-names></name><name><surname>Sluiter</surname><given-names>NR</given-names></name><name><surname>Tibbesma</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>I</given-names></name><name><surname>van de Wiel</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Detection of colorectal cancer in urine using DNA methylation analysis</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>2363</fpage><pub-id pub-id-type="doi">10.1038/S41598-021-81900-6</pub-id><pub-id pub-id-type="pmid">33504902</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Bach S, Paulis I, Sluiter NR, Tibbesma M, Martin I, van de Wiel MA et al (2021) Detection of colorectal cancer in urine using DNA methylation analysis. Sci Rep 11:2363. 10.1038/S41598-021-81900-6<pub-id pub-id-type="pmid">33504902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Bart&#x000e1;k</surname><given-names>BK</given-names></name><name><surname>Kalm&#x000e1;r</surname><given-names>A</given-names></name><name><surname>P&#x000e9;terfia</surname><given-names>B</given-names></name><name><surname>Patai</surname><given-names>&#x000c1;V</given-names></name><name><surname>Galamb</surname><given-names>O</given-names></name><name><surname>Valcz</surname><given-names>G</given-names></name><etal/></person-group><article-title>Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples</article-title><source>Epigenetics</source><year>2017</year><volume>12</volume><fpage>751</fpage><pub-id pub-id-type="doi">10.1080/15592294.2017.1356957</pub-id><pub-id pub-id-type="pmid">28753106</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Bart&#x000e1;k BK, Kalm&#x000e1;r A, P&#x000e9;terfia B, Patai &#x000c1;V, Galamb O, Valcz G et al (2017) Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 12:751. 10.1080/15592294.2017.1356957<pub-id pub-id-type="pmid">28753106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Brenne</surname><given-names>SS</given-names></name><name><surname>Madsen</surname><given-names>PH</given-names></name><name><surname>Pedersen</surname><given-names>IS</given-names></name><name><surname>Hveem</surname><given-names>K</given-names></name><name><surname>Skorpen</surname><given-names>F</given-names></name><name><surname>Krarup</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study</article-title><source>Br J Cancer</source><year>2023</year><volume>2023</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41416-023-02337-4</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Brenne SS, Madsen PH, Pedersen IS, Hveem K, Skorpen F, Krarup HB et al (2023) Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study. Br J Cancer 2023:1&#x02013;8. 10.1038/s41416-023-02337-4</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Cassinotti</surname><given-names>E</given-names></name><name><surname>Melson</surname><given-names>J</given-names></name><name><surname>Liggett</surname><given-names>T</given-names></name><name><surname>Melnikov</surname><given-names>A</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name><name><surname>Replogle</surname><given-names>C</given-names></name><etal/></person-group><article-title>DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps</article-title><source>Int J Cancer J Int Du Cancer</source><year>2012</year><volume>131</volume><fpage>1153</fpage><pub-id pub-id-type="doi">10.1002/IJC.26484</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Cassinotti E, Melson J, Liggett T, Melnikov A, Yi Q, Replogle C et al (2012) DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer J Int Du Cancer 131:1153. 10.1002/IJC.26484</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Performance of a novel blood-based early colorectal cancer screening assay in remaining serum after the blood biochemical test</article-title><source>Dis Markers</source><year>2019</year><volume>2019</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1155/2019/5232780</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Chen Y, Wang Z, Zhao G, Sun C, Ma Y, Zhang L et al (2019) Performance of a novel blood-based early colorectal cancer screening assay in remaining serum after the blood biochemical test. Dis Markers 2019:1&#x02013;6. 10.1155/2019/5232780</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>YC</given-names></name><name><surname>Wu</surname><given-names>PH</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>Huang</surname><given-names>JL</given-names></name><name><surname>Chou</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Using comorbidity pattern analysis to detect reliable methylated genes in colorectal cancer verified by stool dna test</article-title><source>Genes (Basel)</source><year>2021</year><volume>12</volume><fpage>1539</fpage><pub-id pub-id-type="doi">10.3390/GENES12101539/S1</pub-id><pub-id pub-id-type="pmid">34680934</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Cheng YC, Wu PH, Chen YJ, Yang CH, Huang JL, Chou YC et al (2021) Using comorbidity pattern analysis to detect reliable methylated genes in colorectal cancer verified by stool dna test. Genes (Basel) 12:1539. 10.3390/GENES12101539/S1<pub-id pub-id-type="pmid">34680934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>NY</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Shin</surname><given-names>YJ</given-names></name><name><surname>Kang</surname><given-names>JK</given-names></name><name><surname>Song</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Blood-based detection of colorectal cancer using cancer-specific DNA methylation markers</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.3390/DIAGNOSTICS11010051</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Cho NY, Park JW, Wen X, Shin YJ, Kang JK, Song SH et al (2021) Blood-based detection of colorectal cancer using cancer-specific DNA methylation markers. Diagnostics 11:51. 10.3390/DIAGNOSTICS11010051</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Ciarloni</surname><given-names>L</given-names></name><name><surname>Ehrensberger</surname><given-names>SH</given-names></name><name><surname>Imaizumi</surname><given-names>N</given-names></name><name><surname>Monnier-Benoit</surname><given-names>S</given-names></name><name><surname>Nichita</surname><given-names>C</given-names></name><name><surname>Myung</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Development and clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><fpage>4604</fpage><lpage>4611</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2057</pub-id><pub-id pub-id-type="pmid">27126992</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ciarloni L, Ehrensberger SH, Imaizumi N, Monnier-Benoit S, Nichita C, Myung SJ et al (2016) Development and clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer. Clin Cancer Res 22:4604&#x02013;4611. 10.1158/1078-0432.CCR-15-2057<pub-id pub-id-type="pmid">27126992</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>JQ</given-names></name><name><surname>Zhao</surname><given-names>WF</given-names></name><name><surname>Lu</surname><given-names>QW</given-names></name><name><surname>Zha</surname><given-names>FR</given-names></name><name><surname>Bin</surname><given-names>Lv L</given-names></name><name><surname>Ye</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Fecal microbial biomarkers combined with multi-target stool DNA test improve diagnostic accuracy for colorectal cancer</article-title><source>World J Gastrointest Oncol</source><year>2023</year><volume>15</volume><fpage>1424</fpage><pub-id pub-id-type="doi">10.4251/WJGO.V15.I8.1424</pub-id><pub-id pub-id-type="pmid">37663945</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Fan JQ, Zhao WF, Lu QW, Zha FR, Bin Lv L, Ye GL et al (2023) Fecal microbial biomarkers combined with multi-target stool DNA test improve diagnostic accuracy for colorectal cancer. World J Gastrointest Oncol 15:1424. 10.4251/WJGO.V15.I8.1424<pub-id pub-id-type="pmid">37663945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Gagrat</surname><given-names>ZD</given-names></name><name><surname>Krockenberger</surname><given-names>M</given-names></name><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Gagrat</surname><given-names>BZ</given-names></name><name><surname>Leduc</surname><given-names>CM</given-names></name><name><surname>Matter</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Next-generation multi-target stool DNA panel accurately detects colorectal cancer and advanced precancerous lesions</article-title><source>Cancer Prev Res (Phila)</source><year>2024</year><volume>17</volume><fpage>119</fpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-23-0285</pub-id><pub-id pub-id-type="pmid">38224564</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Gagrat ZD, Krockenberger M, Bhattacharya A, Gagrat BZ, Leduc CM, Matter MB et al (2024) Next-generation multi-target stool DNA panel accurately detects colorectal cancer and advanced precancerous lesions. Cancer Prev Res (Phila) 17:119. 10.1158/1940-6207.CAPR-23-0285<pub-id pub-id-type="pmid">38224564</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>H-Y</given-names></name><name><surname>Bai</surname><given-names>E-Q</given-names></name><name><surname>Luo</surname><given-names>Y-X</given-names></name><name><surname>Fu</surname><given-names>R-J</given-names></name><name><surname>He</surname><given-names>Y-S</given-names></name><etal/></person-group><article-title>Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer</article-title><source>Cancer Genet Cytogenet</source><year>2010</year><volume>202</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2010.05.018</pub-id><pub-id pub-id-type="pmid">20804913</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">He Q, Chen H-Y, Bai E-Q, Luo Y-X, Fu R-J, He Y-S et al (2010) Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet 202:1&#x02013;10. 10.1016/j.cancergencyto.2010.05.018<pub-id pub-id-type="pmid">20804913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Imperiale</surname><given-names>TF</given-names></name><name><surname>Gagrat</surname><given-names>ZD</given-names></name><name><surname>Krockenberger</surname><given-names>M</given-names></name><name><surname>Porter</surname><given-names>K</given-names></name><name><surname>Ziegler</surname><given-names>E</given-names></name><name><surname>Leduc</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Algorithm development and early performance evaluation of a next-generation multitarget stool DNA screening test for colorectal cancer</article-title><source>Gastro Hep Adv</source><year>2024</year><volume>3</volume><fpage>740</fpage><pub-id pub-id-type="doi">10.1016/J.GASTHA.2024.05.002</pub-id><pub-id pub-id-type="pmid">39280922</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Imperiale TF, Gagrat ZD, Krockenberger M, Porter K, Ziegler E, Leduc CM et al (2024) Algorithm development and early performance evaluation of a next-generation multitarget stool DNA screening test for colorectal cancer. Gastro Hep Adv 3:740. 10.1016/J.GASTHA.2024.05.002<pub-id pub-id-type="pmid">39280922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Itzkowitz</surname><given-names>SH</given-names></name><name><surname>Jandorf</surname><given-names>L</given-names></name><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Rabeneck</surname><given-names>L</given-names></name><name><surname>Schroy</surname><given-names>PC</given-names></name><name><surname>Sontag</surname><given-names>S</given-names></name><etal/></person-group><article-title>Improved fecal DNA test for colorectal cancer screening</article-title><source>Clin Gastroenterol Hepatol</source><year>2007</year><volume>5</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2006.10.006</pub-id><pub-id pub-id-type="pmid">17161655</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, Sontag S et al (2007) Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 5:111&#x02013;117. 10.1016/j.cgh.2006.10.006<pub-id pub-id-type="pmid">17161655</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>HH</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Bin</surname><given-names>Lin M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Novel multiplex stool-based assay for the detection of early-stage colon cancer in a Chinese population</article-title><source>World J Gastroenterol</source><year>2022</year><volume>28</volume><fpage>2705</fpage><pub-id pub-id-type="doi">10.3748/WJG.V28.I24.2705</pub-id><pub-id pub-id-type="pmid">35979157</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Jiang HH, Tang X, Lin K, Bin Lin M, Chen Y, He LW et al (2022) Novel multiplex stool-based assay for the detection of early-stage colon cancer in a Chinese population. World J Gastroenterol 28:2705. 10.3748/WJG.V28.I24.2705<pub-id pub-id-type="pmid">35979157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein Kranenbarg</surname><given-names>RAM</given-names></name><name><surname>Vali</surname><given-names>AH</given-names></name><name><surname>IJzermans</surname><given-names>JNM</given-names></name><name><surname>Pisanic</surname><given-names>TR</given-names></name><name><surname>Wang</surname><given-names>TH</given-names></name><name><surname>Azad</surname><given-names>N</given-names></name><etal/></person-group><article-title>High performance methylated DNA markers for detection of colon adenocarcinoma</article-title><source>Clin Epigenetics</source><year>2021</year><volume>13</volume><fpage>218</fpage><pub-id pub-id-type="doi">10.1186/S13148-021-01206-2</pub-id><pub-id pub-id-type="pmid">34903270</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Klein Kranenbarg RAM, Vali AH, IJzermans JNM, Pisanic TR, Wang TH, Azad N et al (2021) High performance methylated DNA markers for detection of colon adenocarcinoma. Clin Epigenetics 13:218. 10.1186/S13148-021-01206-2<pub-id pub-id-type="pmid">34903270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Bo</surname><given-names>BL</given-names></name><name><surname>Eun</surname><given-names>JL</given-names></name><name><surname>Eun</surname><given-names>HJ</given-names></name><name><surname>Chun</surname><given-names>HK</given-names></name><name><surname>Dong</surname><given-names>KC</given-names></name><name><surname>Sang</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>6185</fpage><lpage>6191</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0111</pub-id><pub-id pub-id-type="pmid">19773381</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Bo BL, Eun JL, Eun HJ, Chun HK, Dong KC, Sang YS et al (2009) Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15:6185&#x02013;6191. 10.1158/1078-0432.CCR-09-0111<pub-id pub-id-type="pmid">19773381</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Detection of colorectal cancer in circulating cell-free DNA by methylated CpG tandem amplification and sequencing</article-title><source>Clin Chem</source><year>2019</year><volume>65</volume><fpage>916</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1373/CLINCHEM.2019.301804</pub-id><pub-id pub-id-type="pmid">31010820</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Li J, Zhou X, Liu X, Ren J, Wang J, Wang W et al (2019) Detection of colorectal cancer in circulating cell-free DNA by methylated CpG tandem amplification and sequencing. Clin Chem 65:916&#x02013;926. 10.1373/CLINCHEM.2019.301804<pub-id pub-id-type="pmid">31010820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Lidgard</surname><given-names>GP</given-names></name><name><surname>Domanico</surname><given-names>MJ</given-names></name><name><surname>Bruinsma</surname><given-names>JJ</given-names></name><name><surname>Light</surname><given-names>J</given-names></name><name><surname>Gagrat</surname><given-names>ZD</given-names></name><name><surname>Oldham-Haltom</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia</article-title><source>Clin Gastroenterol Hepatol</source><year>2013</year><volume>11</volume><fpage>1313</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2013.04.023</pub-id><pub-id pub-id-type="pmid">23639600</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Lidgard GP, Domanico MJ, Bruinsma JJ, Light J, Gagrat ZD, Oldham-Haltom RL et al (2013) Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol 11:1313&#x02013;1318. 10.1016/j.cgh.2013.04.023<pub-id pub-id-type="pmid">23639600</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Evaluation of combined detection of multigene mutation and SDC2/SFRP2 methylation in stool specimens for colorectal cancer early diagnosis</article-title><source>Int J Colorectal Dis</source><year>2022</year><volume>37</volume><fpage>1231</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1007/S00384-022-04170-2/FIGURES/3</pub-id><pub-id pub-id-type="pmid">35499710</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Lin J, Zhang L, Chen M, Chen J, Wu Y, Wang T et al (2022) Evaluation of combined detection of multigene mutation and SDC2/SFRP2 methylation in stool specimens for colorectal cancer early diagnosis. Int J Colorectal Dis 37:1231&#x02013;1238. 10.1007/S00384-022-04170-2/FIGURES/3<pub-id pub-id-type="pmid">35499710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ming</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>DNA methylation analysis of the SDC2, SEPT9 and VIM genes in fecal DNA for colorectal cancer diagnosis</article-title><source>BMC Cancer</source><year>2024</year><volume>24</volume><fpage>1205</fpage><pub-id pub-id-type="doi">10.1186/S12885-024-12990-4</pub-id><pub-id pub-id-type="pmid">39350171</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Liu Y, Ming H, Xu L, Li L, Liu Q, Zhao J et al (2024) DNA methylation analysis of the SDC2, SEPT9 and VIM genes in fecal DNA for colorectal cancer diagnosis. BMC Cancer 24:1205. 10.1186/S12885-024-12990-4<pub-id pub-id-type="pmid">39350171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Lohsiriwat</surname><given-names>V</given-names></name><name><surname>Mongkhonsupphawan</surname><given-names>A</given-names></name><name><surname>Ovartchaiyapong</surname><given-names>P</given-names></name></person-group><article-title>Diagnostic accuracy of multitarget stool DNA test for colorectal cancer screening and detecting in Thailand</article-title><source>Asian Pac J Cancer Prev</source><year>2024</year><volume>25</volume><fpage>3661</fpage><pub-id pub-id-type="doi">10.31557/APJCP.2024.25.10.3661</pub-id><pub-id pub-id-type="pmid">39471034</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Lohsiriwat V, Mongkhonsupphawan A, Ovartchaiyapong P (2024) Diagnostic accuracy of multitarget stool DNA test for colorectal cancer screening and detecting in Thailand. Asian Pac J Cancer Prev 25:3661. 10.31557/APJCP.2024.25.10.3661<pub-id pub-id-type="pmid">39471034</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><etal/></person-group><article-title>DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA</article-title><source>Oncol Lett</source><year>2014</year><volume>8</volume><fpage>1751</fpage><pub-id pub-id-type="doi">10.3892/OL.2014.2413</pub-id><pub-id pub-id-type="pmid">25202404</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Lu H, Huang S, Zhang X, Wang D, Zhang X, Yuan X et al (2014) DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol Lett 8:1751. 10.3892/OL.2014.2413<pub-id pub-id-type="pmid">25202404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A novel stool methylation test for the non-invasive screening of gastric and colorectal cancer</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>860701</fpage><pub-id pub-id-type="doi">10.3389/FONC.2022.860701/FULL</pub-id><pub-id pub-id-type="pmid">35419280</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Ma L, Gong J, Zhao M, Kong X, Gao P, Jiang Y et al (2022) A novel stool methylation test for the non-invasive screening of gastric and colorectal cancer. Front Oncol 12:860701. 10.3389/FONC.2022.860701/FULL<pub-id pub-id-type="pmid">35419280</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Melotte</surname><given-names>V</given-names></name><name><surname>Yi</surname><given-names>JM</given-names></name><name><surname>Lentjes</surname><given-names>MHFM</given-names></name><name><surname>Smits</surname><given-names>KM</given-names></name><name><surname>Van Neste</surname><given-names>L</given-names></name><name><surname>Niessen</surname><given-names>HEC</given-names></name><etal/></person-group><article-title>Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood</article-title><source>Cancer Prev Res</source><year>2015</year><volume>8</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-14-0198</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Melotte V, Yi JM, Lentjes MHFM, Smits KM, Van Neste L, Niessen HEC et al (2015) Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood. Cancer Prev Res 8:157&#x02013;164. 10.1158/1940-6207.CAPR-14-0198</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Fecal multidimensional assay for non-invasive detection of colorectal cancer: fecal immunochemical test, stool DNA mutation, methylation, and intestinal bacteria analysis</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>183</fpage><pub-id pub-id-type="doi">10.3389/FONC.2021.643136/BIBTEX</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Mo S, Wang H, Han L, Xiang W, Dai W, Zhao P et al (2021) Fecal multidimensional assay for non-invasive detection of colorectal cancer: fecal immunochemical test, stool DNA mutation, methylation, and intestinal bacteria analysis. Front Oncol 11:183. 10.3389/FONC.2021.643136/BIBTEX</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia</article-title><source>Clin Chim Acta</source><year>2020</year><volume>501</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/J.CCA.2019.12.001</pub-id><pub-id pub-id-type="pmid">31816287</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Mu J, Huang Y, Cai S, Li Q, Song Y, Yuan Y et al (2020) Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia. Clin Chim Acta 501:42&#x02013;47. 10.1016/J.CCA.2019.12.001<pub-id pub-id-type="pmid">31816287</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SK</given-names></name><name><surname>Baek</surname><given-names>HL</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>HJ</given-names></name><name><surname>Jung</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population?</article-title><source>Intest Res</source><year>2017</year><volume>15</volume><fpage>495</fpage><pub-id pub-id-type="doi">10.5217/IR.2017.15.4.495</pub-id><pub-id pub-id-type="pmid">29142517</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Park SK, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS et al (2017) Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res 15:495. 10.5217/IR.2017.15.4.495<pub-id pub-id-type="pmid">29142517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Pasha</surname><given-names>HF</given-names></name><name><surname>Radwan</surname><given-names>MI</given-names></name><name><surname>Yehia</surname><given-names>AM</given-names></name><name><surname>Toam</surname><given-names>MM</given-names></name></person-group><article-title>Circulating methylated RUNX3 and SFRP1 genes as a noninvasive panel for early detection of colorectal cancer</article-title><source>Eur J Gastroenterol Hepatol</source><year>2019</year><volume>31</volume><fpage>1342</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000001532</pub-id><pub-id pub-id-type="pmid">31524773</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Pasha HF, Radwan MI, Yehia AM, Toam MM (2019) Circulating methylated RUNX3 and SFRP1 genes as a noninvasive panel for early detection of colorectal cancer. Eur J Gastroenterol Hepatol 31:1342&#x02013;1349. 10.1097/MEG.0000000000001532<pub-id pub-id-type="pmid">31524773</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>SL</given-names></name><name><surname>Krarup</surname><given-names>HB</given-names></name><name><surname>Sunesen</surname><given-names>KG</given-names></name><name><surname>Johansen</surname><given-names>MB</given-names></name><name><surname>Stender</surname><given-names>MT</given-names></name><name><surname>Pedersen</surname><given-names>IS</given-names></name><etal/></person-group><article-title>Hypermethylated DNA, a circulating biomarker for colorectal cancer detection</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0180809</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Rasmussen SL, Krarup HB, Sunesen KG, Johansen MB, Stender MT, Pedersen IS et al (2017) Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS One 12:1&#x02013;13. 10.1371/journal.pone.0180809</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Shan</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group><article-title>A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population</article-title><source>J Cancer Res Clin Oncol</source><year>2019</year><volume>145</volume><fpage>2423</fpage><lpage>2432</lpage><pub-id pub-id-type="doi">10.1007/S00432-019-02992-2/FIGURES/4</pub-id><pub-id pub-id-type="pmid">31456088</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Sun M, Liu J, Hu H, Guo P, Shan Z, Yang H et al (2019) A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population. J Cancer Res Clin Oncol 145:2423&#x02013;2432. 10.1007/S00432-019-02992-2/FIGURES/4<pub-id pub-id-type="pmid">31456088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Tagore</surname><given-names>KS</given-names></name><name><surname>Lawson</surname><given-names>MJ</given-names></name><name><surname>Yucaitis</surname><given-names>JA</given-names></name><name><surname>Gage</surname><given-names>R</given-names></name><name><surname>Orr</surname><given-names>T</given-names></name><name><surname>Shuber</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia</article-title><source>Clin Colorectal Cancer</source><year>2003</year><volume>3</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.3816/CCC.2003.N.011</pub-id><pub-id pub-id-type="pmid">12777192</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP et al (2003) Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 3:47&#x02013;53. 10.3816/CCC.2003.N.011<pub-id pub-id-type="pmid">12777192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>He</surname><given-names>KX</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>QQ</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>A new method for the detection of colorectal cancer and the precancerous lesions: occult blood testing combination with promoter methylation in the fecal sample</article-title><source>J Cancer</source><year>2021</year><volume>12</volume><fpage>335</fpage><pub-id pub-id-type="doi">10.7150/JCA.50525</pub-id><pub-id pub-id-type="pmid">33391430</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Wang DY, He KX, Huang Y, Lou QQ, He T, Xu X (2021) A new method for the detection of colorectal cancer and the precancerous lesions: occult blood testing combination with promoter methylation in the fecal sample. J Cancer 12:335. 10.7150/JCA.50525<pub-id pub-id-type="pmid">33391430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Zong</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Detection of circulating tumor DNA methylation in diagnosis of colorectal cancer</article-title><source>Clin Transl Gastroenterol</source><year>2021</year><volume>12</volume><fpage>E00386</fpage><pub-id pub-id-type="doi">10.14309/CTG.0000000000000386</pub-id><pub-id pub-id-type="pmid">34382948</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Xu F, Yu S, Han J, Zong M, Tan Q, Zeng X et al (2021) Detection of circulating tumor DNA methylation in diagnosis of colorectal cancer. Clin Transl Gastroenterol 12:E00386. 10.14309/CTG.0000000000000386<pub-id pub-id-type="pmid">34382948</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening</article-title><source>Oncol Lett</source><year>2020</year><volume>20</volume><fpage>1193</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.3892/OL.2020.11674/HTML</pub-id><pub-id pub-id-type="pmid">32724359</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Yang C, Wu W, Yang Y, Yang X, Sun J, Zhang W et al (2020) Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening. Oncol Lett 20:1193&#x02013;1200. 10.3892/OL.2020.11674/HTML<pub-id pub-id-type="pmid">32724359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>GP</given-names></name><name><surname>Symonds</surname><given-names>EL</given-names></name><name><surname>Nielsen</surname><given-names>HJ</given-names></name><name><surname>Ferm</surname><given-names>L</given-names></name><name><surname>Christensen</surname><given-names>IJ</given-names></name><name><surname>Dekker</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer</article-title><source>Clin Epigenetics</source><year>2021</year><volume>13</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/S13148-020-00999-Y</pub-id><pub-id pub-id-type="pmid">33478584</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Young GP, Symonds EL, Nielsen HJ, Ferm L, Christensen IJ, Dekker E et al (2021) Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer. Clin Epigenetics 13:14. 10.1186/S13148-020-00999-Y<pub-id pub-id-type="pmid">33478584</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>OSMR and SEPT9: promising biomarkers for detection of colorectal cancer based on blood-based tests</article-title><source>Transl Cancer Res</source><year>2016</year><volume>5</volume><fpage>131</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.21037/TCR.2016.03.07</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Yuan P, Cheng X, Wu X, Li L, Zhang L, Li Z et al (2016) OSMR and SEPT9: promising biomarkers for detection of colorectal cancer based on blood-based tests. Transl Cancer Res 5:131&#x02013;9. 10.21037/TCR.2016.03.07</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>YQ</given-names></name><name><surname>Wu</surname><given-names>YQ</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name></person-group><article-title>Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer</article-title><source>World J Gastroenterol: WJG</source><year>2014</year><volume>20</volume><fpage>6329</fpage><pub-id pub-id-type="doi">10.3748/WJG.V20.I20.6329</pub-id><pub-id pub-id-type="pmid">24876755</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Zhang H, Zhu YQ, Wu YQ, Zhang P, Qi J (2014) Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol: WJG 20:6329. 10.3748/WJG.V20.I20.6329<pub-id pub-id-type="pmid">24876755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Dou</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><etal/></person-group><article-title>SDC2 and TFPI2 methylation in stool samples as an integrated biomarker for early detection of colorectal cancer</article-title><source>Cancer Manag Res</source><year>2021</year><volume>13</volume><fpage>3601</fpage><pub-id pub-id-type="doi">10.2147/CMAR.S300861</pub-id><pub-id pub-id-type="pmid">33958894</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Zhang W, Yang C, Wang S, Xiang Z, Dou R, Lin Z et al (2021) SDC2 and TFPI2 methylation in stool samples as an integrated biomarker for early detection of colorectal cancer. Cancer Manag Res 13:3601. 10.2147/CMAR.S300861<pub-id pub-id-type="pmid">33958894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening</article-title><source>Cancer Med</source><year>2019</year><volume>8</volume><fpage>5619</fpage><lpage>5628</lpage><pub-id pub-id-type="doi">10.1002/CAM4.2475</pub-id><pub-id pub-id-type="pmid">31407497</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Zhao G, Li H, Yang Z, Wang Z, Xu M, Xiong S et al (2019) Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening. Cancer Med 8:5619&#x02013;5628. 10.1002/CAM4.2475<pub-id pub-id-type="pmid">31407497</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Methylated SFRP2 and SDC2 in stool specimens for colorectal cancer early detection: a cost-effective strategy for Chinese population</article-title><source>J Cancer</source><year>2021</year><volume>12</volume><fpage>2665</fpage><pub-id pub-id-type="doi">10.7150/JCA.52478</pub-id><pub-id pub-id-type="pmid">33854626</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Zhao G, Liu X, Liu Y, Ma Y, Yang J, Li H et al (2021) Methylated SFRP2 and SDC2 in stool specimens for colorectal cancer early detection: a cost-effective strategy for Chinese population. J Cancer 12:2665. 10.7150/JCA.52478<pub-id pub-id-type="pmid">33854626</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>S</given-names></name><name><surname>Sluiter</surname><given-names>NR</given-names></name><name><surname>Beagan</surname><given-names>JJ</given-names></name><name><surname>Mekke</surname><given-names>JM</given-names></name><name><surname>Ket</surname><given-names>JCF</given-names></name><name><surname>van Grieken</surname><given-names>NCT</given-names></name><etal/></person-group><article-title>Circulating tumor DNA analysis: clinical implications for colorectal cancer patients. A systematic review</article-title><source>JNCI Cancer Spectr</source><year>2019</year><volume>3</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/jncics/pkz042</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Bach S, Sluiter NR, Beagan JJ, Mekke JM, Ket JCF, van Grieken NCT et al (2019) Circulating tumor DNA analysis: clinical implications for colorectal cancer patients. A systematic review. JNCI Cancer Spectr 3:1&#x02013;14. 10.1093/jncics/pkz042</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Ptashkin</surname><given-names>RN</given-names></name><name><surname>Mandelker</surname><given-names>DL</given-names></name><name><surname>Coombs</surname><given-names>CC</given-names></name><name><surname>Bolton</surname><given-names>K</given-names></name><name><surname>Yelskaya</surname><given-names>Z</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors</article-title><source>JAMA Oncol</source><year>2018</year><volume>4</volume><fpage>1589</fpage><pub-id pub-id-type="doi">10.1001/JAMAONCOL.2018.2297</pub-id><pub-id pub-id-type="pmid">29872864</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM et al (2018) Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol 4:1589. 10.1001/JAMAONCOL.2018.2297<pub-id pub-id-type="pmid">29872864</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Sozzi</surname><given-names>G</given-names></name><name><surname>Roz</surname><given-names>L</given-names></name><name><surname>Conte</surname><given-names>D</given-names></name><name><surname>Mariani</surname><given-names>L</given-names></name><name><surname>Andriani</surname><given-names>F</given-names></name><name><surname>Verderio</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effects of prolonged storage of whole plasma or isolated plasma dna on the results of circulating DNA quantification assays</article-title><source>JNCI: J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1848</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/JNCI/DJI432</pub-id><pub-id pub-id-type="pmid">16368947</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P et al (2005) Effects of prolonged storage of whole plasma or isolated plasma dna on the results of circulating DNA quantification assays. JNCI: J Natl Cancer Inst 97:1848&#x02013;50. 10.1093/JNCI/DJI432<pub-id pub-id-type="pmid">16368947</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Parpart-Li</surname><given-names>S</given-names></name><name><surname>Bartlett</surname><given-names>B</given-names></name><name><surname>Popoli</surname><given-names>M</given-names></name><name><surname>Adleff</surname><given-names>V</given-names></name><name><surname>Tucker</surname><given-names>L</given-names></name><name><surname>Steinberg</surname><given-names>R</given-names></name><etal/></person-group><article-title>The effect of preservative and temperature on the analysis of circulating tumor DNA</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><fpage>2471</fpage><lpage>2477</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1691</pub-id><pub-id pub-id-type="pmid">27827317</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R et al (2017) The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res 23:2471&#x02013;2477. 10.1158/1078-0432.CCR-16-1691<pub-id pub-id-type="pmid">27827317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannou</surname><given-names>S</given-names></name><name><surname>Sutherland</surname><given-names>K</given-names></name><name><surname>Sussman</surname><given-names>DA</given-names></name><name><surname>Deshpande</surname><given-names>AR</given-names></name></person-group><article-title>Increasing uptake of colon cancer screening in a medically underserved population with the addition of blood-based testing</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><fpage>966</fpage><pub-id pub-id-type="doi">10.1186/S12885-021-08678-8</pub-id><pub-id pub-id-type="pmid">34454457</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Ioannou S, Sutherland K, Sussman DA, Deshpande AR (2021) Increasing uptake of colon cancer screening in a medically underserved population with the addition of blood-based testing. BMC Cancer 21:966. 10.1186/S12885-021-08678-8<pub-id pub-id-type="pmid">34454457</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>